Novel Insight to Neuroprotective Potential of Curcumin: A Mechanistic Review of Possible Involvement of Mitochondrial Biogenesis and PI3/Akt/ GSK3 or PI3/Akt/CREB/BDNF Signaling Pathways

Niyoosha Kandezi1, Mahsa Mohammadi1, Maryam Ghaffari2, Mina Gholami3, Majid Motaghinejad1*, Sepideh Safari1

1. Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran.
2. Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Chemistry, Pharmaceutical Sciences Branch, Islamic Azad University (IUAPS), Tehran, Iran.
3. Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

Neurodegeneration is a gradual mechanism of neuronal loss arising from numerous cellular and molecular events such as mitochondrial dysfunction, oxidative stress, inflammation, and apoptosis, and the consequence of these processes is neuroplasticity impairment, cognitive diseases, mood-related diseases, and normal cellular activity. Over the last year, major advances have been made in the field of the introduction of herbal compounds with neuroprotective efficacy, one of which is curcumin. Curcumin (diferuloylmethane) is the most abundant turmeric component extracted from the Curcuma longa plant rhizomes. Accumulating evidence indicates that curcumin may induce mitochondrial biogenesis and can function as an antioxidant, anti-inflammatory, and anti-apoptotic agent, which may be used effectively to treat chronic neurodegenerative diseases and any situation in which the neurodegeneration process takes place. Curcumin has been shown to play a critical role in activating two essential signaling pathways phosphatidylinositol-3(PI3)/ protein kinase B(Akt)/ glycogen synthase kinase-3 (GSK3) and PI3/Akt/cAMP response element-binding protein (CREB)/brain-derived neurotrophic factor (BDNF) and preventing the incidence of neurodegeneration via these two pathways. Curcumin’s protective functions against neural cell degeneration due to mitochondrial dysfunction and consequent events such as oxidative stress, inflammation, and apoptosis in neural cells have been documented and clinical data have increased to suggest that curcumin may be a standard candidate as a neuroprotective agent. Therefore, in this review, we summarized the clinical and experimental studies and interpreted the key contributory mechanisms of neuroprotective properties of curcumin in neurodegenerative diseases and disorders. We also tried to understand the function of PI3/Akt/GSK3 and PI3/Akt/CREB/BDNF signaling pathways in the neuroprotective properties of curcumin and tried to evaluate their association with antioxidant, anti-inflammatory, anti-apoptosis and biogenesis effects of mitochondria.

Key words: Curcumin, neuroprotection, PI3/Akt/GSK3, PI3/Akt/CREB/BDNF

*Corresponding author: Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran.
Email: Dr.motaghinejad6@gmail.com

This work is published as an open access article distributed under the terms of the Creative Commons Attribution 4.0 License (http://creativecommons.org/licenses/by-nc/4). Non-commercial uses of the work are permitted, provided the original work is properly cited.
Neurodegeneration is characterized by progressive neuronal loss that is correlated with multiple cellular and molecular mechanisms resulting in neuroplastic dysfunction, cognitive impairment, and mood-related behavior (1, 2). Neuroprotection concepts are complex and include preventing cell death and restoring activity to damaged neurons, as well as restoring neuronal numbers and behavioral output (3, 4). Based on biological description, neuroprotective agents must be able to restore neural regeneration and maintain normal cellular function and behavior. Previous studies suggested that the protection of neural activity and behavioral functions such as learning and memory, may be good criteria for assessing a neuroprotective agent. On the other hand, there should be a clear correlation between the ability of one neural survival induction agent, neuroplasticity, and cognitive performance to receive the title of neuroprotective (4, 5). There are four distinctive methods for conferring neuroprotection according to the basic principle of neurodegenerative treatment: (1) antagonizing cytotoxic causal events (excess intracellular Ca\(^{2+}\), accumulation of irregular proteins, excitotoxic effects of amino acids, oxidative stress, inflammation-related processes etc.); (2) stimulating endogenous protective processes (anti-free radical or DNA repair systems, neurotrophic factor development, possible steroid cyto-protective action, etc.); (3) promoting damaged structure repair strategies (grafts) or deep brain or cortical neuro-stimulation to activate possible 'protective' cell mechanisms (beyond symptomatic actions); (4) recovery of neuroplasticity processes by neuroprotection activation including signaling pathways and activation of neurogenesis, and regulation of neurodegenerative associated behavioral disorder such as learning and memory loss, anxiety and depression (4, 5). Under these strategies, the production of drugs to delay or prevent the progression of neurodegenerative diseases and disorder may emerge logically from an enhanced understanding of the etiology and pathogenesis of these diseases and disorders (3, 4). The drawbacks of existing neurodegenerative disease pharmacological therapies have led to comprehensive work into novel natural compounds and non-pharmacological strategies to alter the course of these disorders, while reducing the side effects of drugs (3, 6). There has definitely been considerable improvement in these fields over the past few years with the possibility of the introduction of herbal compounds with "neuroprotective" efficacy (5, 6). Curcumin is one of these herbal compounds that has a high potential as a neuroprotective agent (7). Curcumin (diferuloylmethane) (Figure-1) is the most abundant component of turmeric, extracted from the Curcuma longa plant rhizomes (8, 9). This non-nutritious yellow pigment is a proven nutraceutical dietary phenol, and therefore of great medicinal and pharmacological significance (9). Studies have shown that curcumin can induce cell regeneration and defense in multiple organs such as the brain, cardiovascular system, liver, gastrointestinal system, respiratory system, and improve the functionality of these systems (10-12) (Figure-2).

Recent research has also shown the major effects of curcumin on the control of gene expression in the central nervous system in addition to its neuroprotective effects, which may play an important role in its current therapeutic potential (7, 13, 14). Several experimental and clinical models indicate variable complex underlying mechanisms for curcumin neuroprotective effects including activation and induction of survival molecules and neurotrophic factors, modulation of inflammatory behavior, anti-apoptotic behavior, modulation of oxidative stress, and upregulation of mitochondrial function (9, 14-15). Several studies have recorded the importance of curcumin in neurogenesis, neuronal repair, and neurotoxicity (3, 16). It was proposed that curcumin may have neuroprotective capabilities and could decrease the risk of
Curcumin and neuroprotection

Mitochondrial dysfunction has emerged over the last decades as a common pathological characteristic considered as a "convergence point" for neurodegeneration. Although the quest for cure is still a utopia in the field of neurodegenerative diseases, it is clear that the pathobiology of mitochondria is a significant contributing factor to neurodegenerative events that occur during the course of such diseases (5, 19). Recent findings have demonstrated the mechanisms underlying mitochondrial dysfunction in Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD), with both bioenergetics and functional defects being transversal to all three diseases. Such neurodegenerative disorders are partially the product of a dynamic interplay involving robust changes in the transportation and turnover of mitochondria, leading to a mitoenergetic crisis, synaptic starvation, and eventually neuronal degeneration and loss (20, 21).
In this context, in the last decade mitochondria has emerged as an appealing therapeutic target for tackling such neurodegenerative diseases in a timely manner. Natural and mitochondrial based antioxidants such as curcumin have been widely used to mitigate AD, PD, and HD-related symptomatic and neuropathological features (22, 23). Curcumin has been shown to have important neuro- and mitochondria-protective properties against a broad-spectrum of neurotoxic compounds and neurodegenerative diseases/ injury-associated diseases (23, 24). Several exogenous and endogenous causes, such as age, nuclear and mt- DNA mutations, medications, neurotoxic agents, and misfolded/ aggregated proteins, have been shown to induce mitochondrial dysfunction, which is closely related to the initiation and pathogenesis of neurodegenerative disease (24, 25). Based on in vitro and in vivo data, curcumin has an excellent ability to protect CNS cells against mitochondrial pathology in a wide range of neurodegenerative events and against multiple stimulating factors (e.g., ischemia and substance abuse mediated neurodegeneration by mitochondrial dysfunction), neurotoxic compounds (e.g., methamphetamine, alcohol aluminum, manganese, D-galactose), and adverse effects of certain existing medications on neurodegeneration (e.g., oxaliplatin) as well as misfolded-/aggregated/-mutant protein pathologies (e.g., amyloid β, amyloid precursor protein, and α-synuclein) (24-26). In addition, curcumin performs its mitochondrial defensive properties by: (a) retaining mitochondrial ΔΨm/ increasing mitochondrial fusion activity, mitochondrial biogenesis and synaptic proteins; (b) reducing fission machinery, mitochondrial swelling, lipid peroxidation, protein carbonylation; (c) modulating/ targeting the signaling of phosphor- cyclic AMP response element binding protein (CREB)- brain-derived neurotrophic factor (BDNF) and serine/threonine kinase 1 (AKT)/ glycogen synthase kinase-3 (GSK3); (d) restoring glutathione (GSH) and superoxide dismutase (SOD) levels; and(e) reducing tumor necrosis factor-α (TNF-α) and interleukin (IL-1β) and decreasing certain inflammatory biomarkers (7, 14, 19, 26-31).

The results showed that ongoing curcumin therapy was correlated with reduced dementia levels in brain cognition centers (30, 32, 33). It has been shown that chronic use of curcumin in patients with neurodegenerative disorder can cause gray matter volume increase (33, 34). The amount of hippocampal cells increases following chronic curcumin therapy, possibly because of the neurotrophic effects of curcumin (35, 36). Curcumin has been shown to robustly upregulate neuroprotective protein concentrations of B-cell lymphoma 2 (Bcl-2) in areas of the rodent brains and human neuronal cells (37, 38). Recent studies have shown that chronic curcumin treatment offers robust defense against glutamate and N-methyl- d-aspartate (NMDA) -induced cell death of cultured central nervous system (CNS) neurons, including cerebellar granule cells, hippocampal neurons, and cortical neurons (39, 40). Numerous animal models stated that the neuroprotection against excitotoxicity caused by curcumin consists of multiple mechanisms (40, 41). Those mechanisms include NMDA receptor inhibition, gamma aminobutyric acid (GABA) activation, changes in cellular Ca²⁺ concentration, changes in gene expressions such as upregulation of Bcl-2, downregulation of p53 and Bax, activation of Akt and CREB cell survival factors, as well as modulation of c-Jun N-terminal Kinases (JNK), p38 and mitogen activated protein kinase (MAPKs) (40-46). Through all these pathways, it has been shown that curcumin has antioxidant, anti-inflammatory, anti-apoptotic, immunomodulatory and cell-protective properties as a general mechanism (40-46). Curcumin is reported to be neuroprotective in adult brain ischemic models, and may reduce brain injury by inhibiting neuronal apoptosis (47-49). Curcumin was suggested as a putative agent in the
Curcumin and neuroprotection

treatment of some cell degenerative disorders, and may induce organ function modulation in certain multiple disorders. Also, several studies have pointed out that apoptosis can be prevented to some degree by the protective qualities of curcumin (50, 51). Moreover, the synergistic effects of curcumin on the activation of antioxidant enzymes and mitochondrial biogenesis, and also its properties in inhibiting oxidative stress was documented (52, 53). Studies have also shown that curcumin has antioxidant and anti-inflammatory properties that inhibit large cytokines that cause inflammation (Figure-3) (54, 55).

Several studies indicated that curcumin-based Bcl-2 development facilitates the regeneration of severed axons in mammals (45, 56, 57). An investigation was conducted to determine whether curcumin in rodent hippocampus increases the Bcl-2 levels (45, 58, 59). Such results, offer a clear justification for investigating curcumin as a possible treatment for neurodegenerative diseases (13, 60). Regulation of signal transduction by curcumin within critical brain regions affects the role of multiple neurotransmitter systems, and may thus explain the efficacy of curcumin in protecting neurons. In this article, we reviewed the key components of the main mechanism and signal transduction pathways and targets for the behavior of curcumin, and sought to combine these mechanisms with data emphasizing curcumin's neuroprotective impact.

To find the available evidence and information in the literature on the role of curcumin's neuroprotective properties in preventing or treating...
neurodegenerative disorder and diseases with focus on occurrence of oxidative stress, inflammation, and apoptosis/cell death sequel, searches were performed in many databases such as Web of Science, PubMed, Elsevier Science Direct, Google Scholar, Core Collection, Cochrane, through papers corresponding to the years 1990-2019. It should be noted that "curcumin," "neuroprotection," "neurodegenerative disease," "signaling pathways," "oxidative stress," "apoptosis", and "inflammation" were the search terms and key words for analyzing all published papers in this manner. We have used the MESH term "OR" operator between synonyms keywords and "AND" operator between individual keywords to find articles and documents, as well as articles with the greatest consistency with our objective. For the review of papers, we had included papers which considered both animal and human studies, highlighted the effects of curcumin neuroprotection in neurodegenerative diseases and/or disorders, pinpointed three distinct and distinguishing main mechanisms e.g. antioxidant, anti-inflammatory and anti-apoptosis, and referred to 200 papers. Only two main PI3/Akt/GSK3 and PI3/Akt/CREB/BDNF signaling pathways were selected from all the signaling pathways involved in neuroprotection, and therefore selected and reviewed 20 papers. Also, due to the prevalence of curcumin-related studies and word counting limitations, we avoided evaluating other signaling pathways and focused on PI3/Akt/GSK3 and PI3/Akt /CREB / BDNF.

**Curcumin**

The most significant bioactive chemical constituent of turmeric (golden spice) (61, 62) (Figure-1) is curcumin (a hydrophobic polyphenol). This compound was extracted from *Curcuma longa* rhizome which belongs to the family of Zingiberaceae (9, 62). It has a wide variety of medicinal and pharmacological properties (9, 63, 64).

**Molecular mechanisms involved in neuroprotective effects of curcumin**

**Anti-apoptotic activity**

Apoptosis and programmed cell death play a crucial role in the organism's growth, and since the early stage of CNS formation (65, 66). The outer and intracellular signals are thought to cause apoptotic cell death (65, 67). *In vitro* and *in vivo* studies have shown neuroprotective activities of curcumin (57, 68). Evidence relating in particular to the neuroprotective and anti-apoptotic action of curcumin has been documented recently (69, 70). Experimental studies have shown that curcumin prevents cell death through both intrinsic and extrinsic apoptotic pathways (Figure-4) (71, 72). There is some evidence that chronic curcumin therapy, also at low doses, exhibits neuroprotection in transient focal cerebral ischemia (48, 49, 68, 71).

Anti-apoptotic pathways are involved in the neuroprotective effects caused by curcumin (48, 49, 68, 71). In particular, recent biochemical and immunohistochemistry studies have revealed an enhanced expression and activation of intracellular proteases, in particular caspase-3, which act as initiators and performers of the apoptotic process (1, 73, 74). The role of caspases in apoptotic processes after a neurodegenerative cycle is confirmed by the finding that treatment with caspase inhibitors decreases brain damage caused by neurodegenerative diseases (1, 2, 73-75). Chronic curcumin therapy upregulates *Bcl-2* which encodes an anti-apoptotic protein both *in vitro* and *in vivo*, and decreases the levels of pro-apoptotic proteins p53 and Bax (44-46). These data support the assumption that curcumin-mediated protection against neurodegenerative disease and cerebral ischemia involves anti-apoptotic mechanisms (48, 49, 68, 71). Curcumin has recently been shown to inhibit GSK-3, an enzyme involved in pro-apoptotic signalization (76-78). Hence curcumin's neuroprotective activities may be due in part to GSK-3 inhibition (79, 80). According to a new study, the neuroprotective effects of curcumin were...
Curcumin and neuroprotection

associated with the reduction of apoptotic events in the brain cortex, hippocampus, amygdala and other strategic brain regions (81-83). All of these studies have shown that the anti-apoptotic activity of curcumin in brain areas such as hippocampus and amygdala is responsible for its neuroprotective effects in neurodegeneration cognitive enhancement (16, 84). Many previous studies have shown that in neurodegenerative disorders such as PD, AD and HD and other related conditions, curcumin induces enhancement in cognitive function such as learning and memory (85, 86). Many studies have also shown that curcumin can prevent substance abuse (such as nicotine, alcohol and methamphetamine) mediated hippocampal neurodegeneration, and can improve learning and memory in the subject (44, 46). As mentioned above, improved learning and memory, as well as regulation of mood-related behavior can be a criterion for being a neuroprotective agent, and as revealed by previous studies, some parts of curcumin neuroprotective properties were mediated by inhibition of apoptosis in hippocampus and amygdala, leading to increased cognition in subjects suffering from neurodegeneration (16, 87, 88). Chronic curcumin therapy inhibits activated caspase-3 expression and reduces brain DNA fragmentation during neurodegeneration or after transient focal cerebral ischemia (83, 89).
Curcumin has been found to block important pro-apoptotic molecules (GSK-3, caspase cascades), and enhance survival pathways through extracellular signal-regulated kinase (ERK1/2) and Bax proteins (29, 71). A group of studies suggested that curcumin effectively suppressed apoptosis caused by high Ca\textsuperscript{2+} concentration decline during brain cell toxicity (45, 90, 91). The extra- and intracellular concentration of Ca\textsuperscript{2+} plays a significant role in controlling the switching between pro-survival and pro-apoptotic pathways within the cell (91, 92). Because of changes in Ca\textsuperscript{2+} concentration, curcumin inhibits programmed cell death by either regulating the cell membrane in noradrenergic and dopaminergic neurons, or excessive blockage of apoptosis-associated Ca\textsuperscript{2+}, or inactivation of cytotoxicity based on NMDA (93, 94). Curcumin also inhibits de-phosphorylation-induced apoptosis of protein kinase B and ceramide C2 (N-acetylsphingosine)-induced suppression of GSK-3 and protein phosphate (PP2A) (79, 95).

Using mouse glial cells, it was shown that curcumin can block the executor stage of apoptosis by activating phospholipase C and 3-phosphoinositol kinase (PI-3K) (79, 96). Evidence suggested that curcumin increases the mechanism of apoptosis in cancer cells, and induces synergistic effects of the chemotherapeutic agent in killing the same cells (97, 98). Curcumin activates neurogenesis in brain cells due to blockage of the apoptosis or autophagia associated signaling pathway (16, 99). Curcumin regulates also many factors involved in cell survival pathways including CREB, BDNF, anti-apoptotic protein (Bcl-2), and extracellular signal-regulated protein (ERK)/ mitogen - activated protein (MAP) kinases (28, 100-103). It may upregulate neurogenesis, progenitor cell formation, maturation and survival (86, 104). It has been reported that therapy of subjects with neurodegenerative disease or abused substance mediated neurodegeneration with curcumin exerts regenerative neuro-structural (increased brain cell volume) and neurochemical effects (increased protein level – neural viability and function marker) (105, 106). Data indicate that curcumin can become an effective alternative in neurodegenerative diseases [e.g. AD, HD, PD, and amyotrophic lateral sclerosis], and depressive disorders due to the anti-apoptotic effects, as well as the suppression of pro-apoptotic receptors and the enhancement of pro-survival signals (13, 14).

As non-differentiated precursor cells in the CNS, neural progenitor cells (NPCs) supply new neurons and glial cells to repair damage in the adult brain (107-109). Recently, NPCs have been found to undergo apoptosis. Treatment of NPCs with curcumin significantly inhibited apoptosis. Curcumin could support the survival of NPCs, leading to an increase in neurogenesis (109, 110). Recent results have suggested that curcumin therapy shows heterogeneity in the clinical response to neurodegenerative disorder due to changes in the balance of pro- and anti-apoptotic gene expression (111, 112). Another research investigated the impact of chronic curcumin treatment on the hippocampus, as measured by changes in the subcellular level of apoptosis-regulatory proteins caused by neurotoxin, alcohol and nicotine (113, 114). Robust protective effects against various apoptotic insults caused by b-amyloid have been demonstrated (7, 115). Nearly all data indicate that curcumin blocks the pro-apoptotic signal transmission cascade in neurons; however, a recent study found that this agent can also induce apoptosis in cancer (97, 116). Past research found that curcumin administration had a major effect on neural necrosis caused by abused drugs and neurodegenerative events (44- 46, 77). All of these properties may contribute to curcumin’s potential therapeutic efficacy in neurodegenerative disorders, but the exact mechanism remains unclear. Summary of multiple studies result about curcumin anti-apoptotic effects on various animal models and cell lines is indicated in Table 1.

**Modulation of inflammation**
## Table 1. Summary of multiple studies result about curcumin anti-apoptotic effects on various animal models and cell lines.

| Animal model (rat) | Dose and treatment | Major outcomes | Ref. |
|--------------------|--------------------|----------------|------|
| Animal model of excitotoxicity (rat) | Doses of 0, 1.26, 2.6, 6 and 10μM curcumin for 24 hours on cortical neurons | Curcumin inhibits apoptosis in glutamate-induced cell death and increases BDNF and TrkB expression | 58 |
| Animal model of transient focal cerebral ischemia (rat) | Doses of 100 and 300 mg/kg i.p. 60 minutes after occlusion of the cerebral artery | Curcumin significantly decreased the protein expression of caspase-3. Modulates TUNEL-positive cells and inhibits cell death. | 69 |
| Animal model of traumatic brain injury (TBI)(rat) | Doses of 50 mg/kg administered intraperitoneally 15 min after TBI induction. | Increased expression and nuclear translocation of Nrf2 and enhanced expression of antioxidant enzymes in the TBI model. | 71 |
| Animal model of focal cerebral ischemia-reperfusion(rat) | Doses of 100 mg/kg and 300 mg/kg. | Curcumin improves the symptoms of nerve damage and volume of infarction, reduces the water content of the brain and relieves neuronal apoptosis (Bax level) and also increases the expression of p-MEK, p-ERK, p-CREB, Bcl-2. | 72 and 50 |
| Animal model of cerebral ischemia (rat) | 1 and 2 mg / kg, i.p. 30 min after focal cerebral ischemia / reperfusion | Decreased Nitrites/nitrates contents and TNF(alpha) level | 49 |
| Animal models of nicotine morphine and alcohol-induced neurotoxicity | Doses of 10, 20, 40 and 60 mg / kg curcumin for 21 days i.p.in nicotine or alcohol-dependent rat | Decreased nicotine and/or induced apoptosis, oxidative stress and inflammation and increased levels of P-CREB and BDNF. | 45,46 and 47 |
| N2a / WT cell line and APP / PS1 transgenic mice animal model for Alzheimer pathophysiology detection | Single doses of 1 and 0.16 mg / kg for animals and 5 μM for cell line. | Decreases in Caveolin-1, inactivation of GSK-3 and inhibition of abnormal excessive Tau phosphorylation, inhibition of Bax and increase in Bcl-2 | 81 |
| Animal model of cerebral ischemia (rat) | 100 and 300 mg/kg of curcumin following ischemia | Reduced TUNEL-positive cells and biomarkers of apoptosis in cortex | 80 |
| Hypoxia-hypercapnia rat model | Curcumin at doses of 20, 40, 60 and 80 mg / kg following hypoxia-hypercapnia | Decreases of hypoxia-hypercapnia-induced brain damage and oedema, lowering expression levels of aquaporin (AQP)-4 protein and apoptotic biomarker. | 83 |
| H2O2-induced neurotoxicity of the PC12 cell line | Doses of 12.5–200 μM of curcumin | Attenuation of caspase activation, DNA damage and accumulation of reactive oxygen species (ROS), increase of MAPK and AKT pathways. | 84 |
| Animal model of aged rat | Curcumin was added to feed at 480 mg /kg and the animal was treated for 6 and 12 weeks. | Curcumin enhanced neurogenesis related genes and cognition activity and inhibited apoptotic protein caspase 3. | 17 |
| D-galactose-induced neurodegeneration | Curcumin was administered 50 and 100 mg /kg orally for 63 days. | Reduction of caspase-3, malondialdehyde, enhanced mitochondrial enzymes and glutathione levels and improved cognition | 85 |
| Rat model of Alzheimer disease cognitive defect by streptozotocin, | Curcumin treatments were 5,15, 25, 50, 100 and 200 mg / kg; gavage was performed for 30-60 days. | Increases in neurogenesis and memory recognition and decreases in neuro-inflammation, oxidative stress and apoptosis. Increases in activation capability | 87,88 and 104 |
A significant body of evidence has emerged in recent years indicating that inflammation plays a role in the pathological processes that underlie neurodegenerative disorders and diseases (117, 118). Curcumin has been shown to affect inflammatory mediator levels such as those involved in cyclooxygenase–prostaglandins and nitric oxide synthase–nitric oxide (NOS-NO) pathways, TNF-α, IL-1β, and other cytokines (119-122). Experimental studies have shown that arachidonic acid in the brain may be a target for curcumin (120, 121). Reducing arachidonate turnover can be related to down-regulating gene expression and cytosolic phospholipase A2 enzyme activity induced by curcumin (120, 123-125). Curcumin also decreased the brain protein levels and activity of cyclooxygenase 2 (COX-2) as well as the brain concentration of prostaglandins that are arachidonate metabolites produced by COX-2 (124-126). Accumulating evidence indicates that inflammation plays a role in the pathogenesis of neurodegenerative diseases and disorders, and that curcumin has anti-inflammatory effects that may contribute to its therapeutic effectiveness (13, 14, 60, 127-129). Some data suggest that curcumin exerts anti-inflammatory effects (e.g., suppression...
Curcumin and neuroprotection

of COX-2 expression, inhibition of IL-1\(\beta\) and TNF-\(\alpha\) production, and enhancement of Nf-K\(\beta\) inhibition (130-132). However, there is a broad range of evidence suggesting that curcumin also exhibits anti-inflammatory properties under certain experimental conditions such as drug abuse (44-46, 77). Chronic curcumin therapy has shown a significant decrease in lipopolysaccharide (LPS)-induced elevation of brain prostaglandin E2 (PGE2) synthesis in rats (130). Curcumin reduced LPS-induced upregulation of COX-2 and PGE2 production in rat primary glial cells (130, 133). Similarly, it has been observed that curcumin significantly decreased COX-2 expression and PGE2 production in experimental procedures in neurodegenerative models (122, 130). Several studies have found that curcumin modulates the NOS-NO pathway (122). A recent study found that curcumin pretreatment decreased NOS activity in the ischemic rat model (48, 134). In addition, curcumin has been shown to decrease NOS expression and NO production in rat brain tissue (134, 135). TNF-\(\alpha\) is a cytokine which promotes inflammation. Many studies have shown that curcumin treatment has resulted in a significant dose-dependent reduction in TNF-\(\alpha\) secretion by normal inflammatory cells, especially in brain cells (42, 136). Other studies later also stated that curcumin decreases the development of TNF-\(\alpha\) in neurodegenerative events (14, 129, 137). Furthermore, another study indicated that curcumin treatment decreased in vivo development of TNF-\(\alpha\) in mice treated with LPS (138, 139). In addition, in a rat model of morphine, nicotine, and alcohol mediated neurodegeneration, curcumin was found to decrease hippocampal TNF-\(\alpha\) levels (44-46, 77). Conclusively, the summarized studies show that the effect of curcumin on TNF-\(\alpha\) varies under different experimental conditions, with most studies suggesting that it inhibits TNF-\(\alpha\) synthesis. In subjects with neurodegenerative diseases (128, 129), IL-1\(\beta\) is a pro-inflammatory cytokine. IL-2 is a cytokine that is anti-inflammatory. Numerous studies have shown that curcumin increases the secretion of IL-2 (140, 141). On the other hand, several studies have shown that curcumin does not substantially alter IL-2 levels (138, 142) or decrease IL-2 production (141). Taken together, these data indicate that curcumin inhibits IL-2 development certifying that this neuroprotective agent has an anti-inflammatory impact (143). IL-4 is a cytokine which causes inflammation. The effect of curcumin on IL-4 synthesis in neurodegenerative events (142, 144, 145) was investigated in few studies relative to other inflammatory mediators. Many of those studies showed that curcumin reduced levels of IL-4 (138, 145, 146). Nevertheless, tests have also shown that curcumin does not affect this cytokine (8). IL-6 is a cytokine that is pro-inflammatory. Numerous studies have shown that curcumin in neurodegenerative events attenuates IL-6 production (46, 60, 127, 147). Overall, these data suggest that curcumin's effect on IL-6 varies with different experimental conditions. IL-10 is a cytokine with anti-inflammatory influence. Most of the studies that investigated the effect of curcumin on IL-10 found that it decreased the production of IL-10 (121, 148). About the anti-inflammatory action of curcumin evidence, it has been approved that curcumin reduced the production of INF-\(\gamma\), as pro-inflammatory cytokine, at blood level in neurodegenerative disease. (141). Similarly, evidence has shown that curcumin reduced the production of INF-\(\gamma\) in serum and brain tissue during the neurodegeneration process (27, 149). Predominantly, most of the studies reviewed found that curcumin inhibits INF-\(\gamma\) synthesis, which is a clear indication of possible anti-inflammatory effects (150-152). Some earlier studies have also shown that curcumin induces anti-inflammatory effects on brain regions such as hippocampus and amygdala, which may have protective effects against neurodegenerative diseases, because curcumin can function as a neuroprotective agent,
cognitive enhancer, and mood stabilizer during neurodegeneration due to the role of the hippocampus in cognitive and mood-related behavior (153, 154). Recent research has shown that curcumin prevents the development of inflammatory processes and induces cognitive function (learning and memory) and mood improvement in neurodegenerative diseases and other related conditions including drug abuse mediated neurodegeneration. Accordingly, there is a correlation between the anti-inflammatory effects of curcumin and its effects on cognition enhancement. (44, 46, 85). Studies concluded that certain parts of curcumin neuroprotective properties are mediated by inhibition of neuro-inflammatory pathways in the hippocampus and amygdala, leading to improved cognition and mood-related actions throughout neurodegeneration occurrences (85, 153). The mechanism associated with curcumin's anti-inflammatory effects is still obscured. Among the pharmacological activities of curcumin, CREB activation or GSK-3β inhibition are those which have been documented repeatedly to modify inflammatory responses of different types (44, 46, 155). A strong piece of evidence for a link between CREB and GSK-3β and inflammation (155) has been shown. A growing body of evidence has shown that GSK-3β (inhibition) associated anti-inflammatory effect of curcumin is not exclusively triggered by the inactivation of NF-κB. Another downstream target of GSK-3β is the transcription factor signal transducer and transcription activator (STAT). Inhibition of GSK-3β by curcumin has been found to result in reduced STAT activation, which plays a crucial role in decreasing pro-inflammatory cytokine secretion (160-163). Similar work has also shown that curcumin induces CREB (activation)-associated anti-inflammatory responses that lead to its neuroprotective effectiveness (46, 160, 164).

**Modulation of oxidative stress**

The brain is sensitive to reactive oxygen species (ROS) development because it does not only metabolize 20% of total body oxygen, but also has a restricted antioxidant capacity (165). Consequently, free radical generation exceeds antioxidant capacity. Oxidative stress can lead to degradation of the membrane, cellular dysfunction, and apoptosis (165). Increased oxidative neuronal stress (OxS) has deleterious effects on signal transduction, structural plasticity, and cellular resilience, often by inducing lipid peroxidation in membranes, proteins and genes (166, 167). Additionally, studies show that curcumin exerts neuroprotective effects on oxidative stress. Many studies assessed plasma levels of the metabolism markers (oxidative/energy), thiobarbituric acid reactive substances (TBARS) (a direct index of cell lipid peroxidation), superoxide dismutase (SOD), catalase (CAT), and neuron-specific enolase (NSE) compared to controls in subjects during neurodegenerative disease occurrences (168-174). The elevated SOD/CAT ratio results in increased OxS, and is mainly reflected by elevation in the concentration of hydrogen peroxide in cells (167). Through resistance to OxS, curcumin has proven to exert antioxidant and neuroprotective impact. Similarly, curcumin therapy has been shown to avoid excitotoxicity by inhibiting oxidative stress in brain cells (175, 176). Glutathione, as the main antioxidant in the brain, plays a key role in preventing oxidative damage (177). Previous research found that chronic curcumin therapy

---

Kandezi N et al.
### Table 2. Summary of multiple studies of curcumin anti-inflammatory effects on various animal models and cell lines.

| Cell line/Animal model | Dose, concentration and duration or protocol of treatment | Major outcomes and results | Ref. |
|------------------------|----------------------------------------------------------|---------------------------|------|
| Animal mouse model fetal brain injury | LPS was used to induce mouse fetal brain injury model and the effects of maternal administration of curcumin (40 mg /kg) on the fetal mouse brain were evaluated. | The maternal administration of curcumin alleviates neuro-inflammation in the fetal brain caused by administration of LPS. Long-term consumption of curcumin may improve the neurological outcomes of pre-maturity neonates from dams suffering from infection / inflammation. | 120 |
| HAPI cells have been incubated with their compound and curcumin. | Concentrations of 0.1, 0.5, 1, 10, and 50 μM for 24 h prior to the MTT assay. | The compound is a novel anti-inflammatory agent for the treatment of many neurodegenerative disorders in which microglial activation is a critical step in their pathogenesis. In addition, it has the unique property of mediating both iNOS and COX-2 actions. Four analogs, namely rosmarinic acid, tetrahydrocurcumin, dihydrocurcumin and hexahydrocurcumin, showed a better binding than curcumin. Curcumin analogs have also been found to possess anti-inflammatory activity. This study may lead to a better understanding of inhibition of PLA2 by curcumin analogs. | 123 |
| Molecular docking | All ligand structures have been either downloaded from the PubChem Database or manually drawn using the Marvin Sketch program. In addition to curcumin, a total of 28 curcumin analogs were selected for the studies. | Several derivatives have been able to inhibit the activity of Phospholipase A2, Cyclooxygenase, Lipo-oxygenase, and Microsomal Prostaglandin E Synthase-1. | 124 |
| Human recombinant microsomal enzyme PGE synthase-1, prostaglandin H2(PGH2), and prostaglandin E2(PGE2) were exposed to multiple curcumin structures. | Seven curcumin structure analogues 1, 3, 6, 7, 9, 11, 12 and 17 are exposed to Phospholipase A2, Cyclooxygenase, Lipo-oxygenase and Microsomal Prostaglandin E Synthase-1. | They found that TBI had damaged plasma membranes as evidenced by an increase in lipid peroxidation marker 4-hydroxynonenal (4-HNE) levels. The TBI reduced the NR2B subunit of the NMDA transmembrane receptor. Curcumin inhibited endothelial cell proliferation in a dose-dependent manner and its derivatives demonstrated significant inhibition of bFGF-mediated corneal neo vascularization in the mouse. Curcumin limits the expression of COX-2 by inhibiting the binding of AP-1, NF-k beta and its DNA. | 125 |
| Animal brain trauma model (rat) | Using curcumin supplementation to counteract the effects of traumatic brain injury on homeostasis membrane disruption. | They found that TBI had damaged plasma membranes as evidenced by an increase in lipid peroxidation marker 4-hydroxynonenal (4-HNE) levels. The TBI reduced the NR2B subunit of the NMDA transmembrane receptor. Curcumin inhibited endothelial cell proliferation in a dose-dependent manner and its derivatives demonstrated significant inhibition of bFGF-mediated corneal neo vascularization in the mouse. Curcumin limits the expression of COX-2 by inhibiting the binding of AP-1, NF-k beta and its DNA. | 126 |
| Primary endothelial cells and cornea of the mouse | Curcumin doses ranging from 0 to 20 μM | | |
| Microglial cell culture BV2. | Concentrations of 0.2, 4, 8,16 μM were used for increased nuclear factor κB (NF-κB) and activator protein 1 (AP-1) DNA bindings induced by LPS. | | |
| Female ICR mice (6±7 weeks of age) | 1, 5 or 25 mmol curcumin was used 30 min before cyclooxygenase-2 was induced by phorbol ester in the mouse skin. | Curcumin inhibits the expression of TPA-induced COX-2 by blocking the ERK and NF-κB signaling cascades that provide a molecular basis for the suppression of tumor promotion as well as inflammation in mouse skin by this chemopreventive phytochemical. | 132 |
| Cell line of human colon cancer (colo 205 cells) | Multiple time-conducting concentrations were used in colo 205 cells and inflammatory biomarkers were evaluated. | Curcumin inhibited Cox-2 levels, but promoted Cox-1 levels in colo 205 cells. Curcumin also inhibited levels of MMP-2 and promoted levels of MMP-9, but did not affect levels of MMP-7. Also Dibenzyol methane (DBM), trimethoxy dibenzoyl methane (TDM), tetrahydro curcumin (THC) and curcumin effectively inhibited the release of arachidonic acid and its metabolites in lipopoly saccharide (LPS)-stimulated RAW cells and A23187-stimulated HT-29 cell. |
| Male Sprague-Dawley rats models of hypoxia ischemic brain damage (HIBD), | A set of curcumin (0, 20, 40, 60, 80 mg / kg) was tested in the trials. The 40 mg / kg dose was chosen for the final brain damage induction experiments. | Curcumin protects the BBB ultrastructure and therefore reduces the brain edema following HIBD by lowering the HIBD-induced increase in nitric oxide synthesizes activity and AQP-4 protein expression. |
| Animal model alcohol dependence in adult mice | Four groups with N = 10–12/group: (a) vehicle (corresponding to: physiological saline or 0.1 per cent DMSO, 10 ml /kg), (b) ethanol (1 g / kg), (c) curcumin (40 mg / g) followed by ethanol, (d) DMSO (10 ml / kg) followed by ethanol. | Curcumin can affect acute memory deficits caused by ethanol are mediated, at least in part, by suppressing the activity of nitric oxide synthesizes in the mice’s brain. |
| Animal model of male albino mice with neuropathic pain | Curcumin (60 mg / kg) was injected into a neuropathic pain model. | Uncontrolled 4-week-long diabetes in mice is associated with increased glucose levels of nitrite and TNF-α. Once daily curcumin was administered, nitrite and TNF-α levels were inhibited. |
| The murine of BV2 microglia cell line | The cells were exposed to different concentrations (10, 30, 40, 50μM) of curcumin. | Curcumin plays an important role in the attenuation of LPS-induced inflammatory reactions in microglial cells and that mechanisms involve the down-regulation of PI3K / Akt signaling. |
| T-cell clones and part of the cytomegalovirus chain. | The cells were exposed to different concentrations (10-100μM) of curcumin. | Oral curcumin administration significantly inhibited IL-2 therapy-induced urinary nitrite / nitrate excretion and nitric oxide synthesizes tumor tissue expression, and further increased IL-2 therapy-induced survival prolongation in the murine Meth-A ascites tumor model. |
| Mononuclear cells in peripheral blood | Curcumin (20 μg / ml) was used and IFN-(10 ng / ml), IFN-1 (10 ng / ml) and IL-12 (100 ng / ml) were measured. | Curcumin has a differential effect on IL-12 and IFN-α/β not only by differential effects on STAT4 phosphorylation, but also on the upstream receptor level. |
| Human lymphocytes | Various concentrations of curcumin (2.5, 5, 10, 50μg) | Curcumin has profound immunosuppressive effects mediated by inhibition of IL-2 synthesis, mitogen, and IL-2 induced activation of human lymphocytes. |
| Human keratinocyte cell line | Various concentrations (2-100μg) of curcumin have been exposed to the cell line. | Curcumin attenuates the expression of TNF-α induced IL-18, IL-6, and TNF-α in HaCaT cells as well as inhibition of TNF-α induced NF-kB, p38 MAPK, and JNK activation. |
| Male Wistar rats (90–110 days) infected with Tripanosoma Evansi. | Doses of 0, 20 or 60 mg /kg curcumin after infection. | Curcumin inhibited AChE activity and improved immunological response by pro-inflammatory cytokines. |
| Healthy adult male mice with intracerebral | The dose of 100 mg /kg was used for the ICH model | Curcumin would reduce the number of cerebral T-lymphocytes in experimentally induced ICH mice. |
| Animal model of hemorrhage (ICH) | Various concentrations (1-50μg) of curcumin have been exposed to the cell line. | Curcumin blocked the production of pro-inflammatory and cytotoxic mediators such as NO, TNF-alpha, IL-1alpha, and IL-6 produced by Abeta(25-35)/IFN-gamma and LPS-stimulated microglia. |
|---------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Animal model of renal ischemia/ reperfusion (rats) | Curcumin (10-100 mg /kg) was used prior to ischemia/reperfusion. | Curcumin pretreatment decreases the pulmonary apoptotic pathway by substantial inhibition of TGF-β and caspase-3 in the kidney and lung tissues. |
| Animal model of Gulf War Illness | Dose of 30 mg /kg in 0.1 ml of 33 % DMSO for the treatment of the sequel of the model. | Curcumin treatment enhanced antioxidant gene expression and normalized multiple gene expression related to mitochondrial respiration, inflammation and oxidative stress with normalized mitochondrial respiration that underlie better memory and mood function mediated by curcumin therapy. |
| Animal model of cognitive defect by in diabetic rats. | Dose 100(mg /kg /day, IP) following induction of diabetes. | Nicotin-Curcumin reverses the effects of diabetes mellitus on Bax, Cyt-c, Cleaved Caspase-3, and Bcl-2 protein expression in rat hippocampus CA1 tissue. |
| Animal model of acrylamide-induced spatial memory impairment in male rats | Curcumin (90 mg / kg curcumin by oral gavage) was used in rats treated with acrylamide. | Curcumin alleviated ACR-induced spatial memory impairment through reversing tau abnormalities and P-CREB reduction in the hippocampus. |
| Animal model of arsenic mediated alterations in NMDA receptor. | The oral dose of 20 mg /kg was given to rats treated with arsenic. | Curcumin exercises its neuroprotective influence, affecting the PI3K /Akt pathway, which may affect NMDA receptors and downstream signaling through TrKβ and BDNF in arsenic induced cognitive deficits in the hippocampus. |
| The endometrial cancer cell line | Various concentrations of curcumin (10–50mM) were used for 72 h. | Curcumin has increased PIAS-3 expression in cancer cells. And Curcumin suppresses JAK-STAT signaling by activating PIAS-3, thereby attenuating STAT-3 phosphorylation and tumor cell growth. |
| Acute spinal cord injury in the animal model (rat) | Curcumin was administered at 40 mg /kg by intraperitoneal injection following spinal cord injury. | Curcumin has a moderately protective effect on spinal cord injury and may be associated with inhibition of overexpressed AQP4 and GFAP and activated JAK / STAT signaling pathway. |
| Primary microglia Cells | Various concentrations (2-100μg) of curcumin have been exposed to cell line | Curcumin may increase phosphorylation and association with JAK1/2 of SHP-2, which inhibits the initiation of JAK-STAT inflammatory signaling in activated microglia and inhibits the up-regulation of nitric oxide synthase and COX-2 inactivated microglia. |
| Rodent cortical neurons | Curcumin between 1.25 and 10μM | Curcumin-induced increase in phosphorylate cyclic AMP response element binding protein (CREB) and curcumin neuroprotection may be mediated via BDNF /TrkB-MAPK /PI-3K-CREB signaling pathway. |

increased glutathione levels in primary cultivated rat cerebral cortical cells, and that the effects of curcumin on glutathione levels were dose-dependent in rodent and human experimental procedures with neurodegenerative disease (178-180). Curcumin therapy in neurodegenerative
diseases greatly decreases the levels of lipid peroxides in the brain tissues and increases the antioxidant status (13, 87, 181-183). Curcumin has also been shown to decrease the SOD levels in preclinical experiments relative to animals subjected to a prefrontal cortex animal model of mania (ketamine) (184). Many previous studies demonstrated curcumin's neuroprotective function and explained its mechanism, some of which showed that curcumin can inhibit neurotoxicity by modulating the oxidative stress event (9, 61, 185).

For its antioxidant and radical scavenging properties, curcumin is marketed as the main constituent of turmeric (8, 9). Curcumin strengthens systemic markers of oxidative stress and induces increased activation of the antioxidant balance in substance misuse and other circumstances causing neurodegeneration in humans and animals (44-46, 77). Studies have shown that curcumin can effectively scavenge free radicals in neural damage (38). According to current evidence, curcumin mainly contributes to the reduction of lipid peroxidation in human and animal subjects treated with alcohol (46, 186). Curcumin can prevent neurotoxicity damage by scavenging of these free radicals and inhibiting lipid peroxidation processes (187). Curcumin, therefore, may protect the neural cell membrane from oxidative damage by exerting great efficacy to prevent lipid peroxidation (188). In this scenario, curcumin treatment in animal models (by multiple doses of 5, 10, 40 and 60 mg/kg) in rodents will inhibit neurodegenerative agent malicious effects, and reduce the amount of MDA and lipid peroxidation in brain tissue (31, 44, 46, 57, 189). Previous studies have reported that curcumin has neuroprotective properties; these findings demonstrate the role of curcumin, mediated by the reduction of free radicals in neural cells that are impaired by neurodegenerative disease (3, 107). Has Also, it was shown that various doses of curcumin can increase reduced glutathione content and decrease oxidized glutathione levels in animal models of neurodegenerative disease and associated neurodegenerative disorders (190). Curcumin also neutralizes the adverse effects on the glutathione circle of certain neurotoxic agents (190). These findings were also supported by previous studies demonstrating that curcumin can increase the levels of glutathione in subjects suffering from neurodegenerative disorder (60, 183, 191). It seems that some parts of the neuroprotective properties of curcumin are mediated during the neurodegenerative phase through the modulation of the glutathione circle (183). Curcumin has also been shown to have possible effects on glutathione recovery in vital organs like the brain, liver and kidneys (3, 8). The neuroprotective effects of curcumin were shown to be mediated by the glutathione pathway (3, 183). Curcumin has been shown to increase glutathione and activate the glutathione pathway, and to decrease the development of glutathione sulfide in some subjects diagnosed with drug abuse who suffer from neurodegeneration in their brain (178, 191). Curcumin's antioxidant effects in the regulation of the glutathione pathway against the incidence of neurodegeneration damage have been well established, and it has been shown that an adequate balance between oxidized and reduced glutathione is a crucial factor in the efficacy of the human brain metabolism system (178, 192). In addition, curcumin has been shown to preserve mitochondrial biogenesis and antioxidant physiognomies in strategic organs especially in brain areas (24, 25, 193). Curcumin induces increased production of SOD, glutathione peroxidase (GPx), CAT, and glutathione reductase (GR) activating antioxidant defenses in the brain of neurodegenerative disorder subjects (49, 194). Curcumin has been shown to play a critical role by preserving SOD and GPx activity in neural cells and reversing the CAT inhibition caused by the toxic agent (49). These curcumin functions will eventually contribute to a reduction in lipid.
peroxidation, and thus boost the harmful effects of the signaling pathway to neurodegeneration (7, 12). As indicated by in vivo and in vitro studies, the effect of curcumin on the antioxidant defense mechanism, lipid peroxidation levels, neural cell ROS and NOS levels have been confirmed (195). Through activating GR, curcumin enhances the conversion of oxidized to reduced glutathione, thereby shielding neuronal cells from the initiation of oxidative stress in neurodegenerative diseases (196). As disused above, some parts of curcumin-induced neuroprotection mediated through its properties in improving cognition of neurodegenerative diseases and disorders were due to its anti-inflammatory and anti-apoptosis properties (16). In line with this idea, some previous studies showed that curcumin induces antioxidant effects on brain areas such as hippocampus and amygdale, and may reduce cognitive deficits throughout neurodegeneration (153, 197). These studies have shown that curcumin can inhibit lipid peroxidation and ROS and NOS production in hippocampus and amygdale, and also stimulate antioxidant enzyme activity such as SOD, GPx, and GR in the mentioned brain region, and that this antioxidant mechanism will probably function as a neuroprotective agent, cognitive enhancer and mood stabilizer during neurodegeneration occurrences (44-46, 198). Such findings indicated that certain portions of curcumin neuroprotective properties as a cognitive enhancer were mediated by inhibition of oxidative stress damage in the hippocampus and amygdala, resulting in normalization of memory and mood-related actions throughout neurodegeneration occurrences (44-46, 198). All of these studies have shown that curcumin possesses the potential capacity for free radical scavenging and activation of antioxidant enzyme in neural cells exposed to neurotoxic or neurodegenerative agents and neurodegenerative disease subjects in both animals and humans. In addition, as oxidative stress is involved in most neurodegenerative event studies, curcumin’s possible protective role as an antioxidant against this form of failure has been investigated. Summary of multiple studies results about curcumin’s antioxidant effects on various animal models and cell lines is indicated in Table 3.

Upregulation of mitochondrial function

With transcriptional control (199), mitochondria plays a key role in cells including energy homeostasis, metabolism, signaling and apoptosis. Transcriptional mechanisms that control biogenesis and function of mitochondria may shed light on potential therapeutic approaches to modulate mitochondrial function (200). Many human diseases, particularly neurodegenerative diseases (200), are associated with mitochondrial dysfunctions. Curcumin prevents the mitochondrial release of proteins associated with apoptosis (25, 193, 201, 202). Weak punctata cytoplasmic immunostaining indicated that under normal conditions cytochrome c (Cyt c) is located in the intermembrane space of the mitochondria (203). In damaged areas, Cyt c is released into the cytoplasm from the mitochondria, causing extreme neuronal, cytoplasmic staining (203). Apoptosis-inducing factor (AIF) is another protein that is usually located in the mitochondrial space of the intermembrane, translocating from injured cells into the nucleus (199, 203). Curcumin treatment decreased the number of AIF positive nuclei 24 h after treatment in the hippocampus, and immunoblotting confirmed that curcumin inhibited the AIF release from the mitochondrial fraction in neurodegenerative animal modeling (204, 205). Recent studies have shown that curcumin in hippocampal cells induced an increase in mitochondrial mass leading to increased production of ATP with major improvements in mitochondrial efficiency (45, 113, 206). This increase in mitochondrial mass was associated with an increase in mRNA levels of mitochondrial biogenesis transcription factors (84, 193), some of which
Table 3. Summary of multiple studies of curcumin antioxidant properties and its effects on mitochondrial function on various animal models and cell lines.

| Cell line/Animal model                                                                 | Dose, concentration and duration or protocol of treatment | Major outcomes and results                                                                                                                                                                                                 | Ref. |
|---------------------------------------------------------------------------------------|----------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| Cortical astrocytes and neurons cell culture                                          | Concentration of 5, 10, 20, 50 or 100 μM curcumin for 24 hours on cortical neurons | Curcumin reduced GSSG and increased GSH. Increased cell viability also reduced oxidative stress related gene expression. Curcumin also decreased caspase 3 and Bax and increased protein Bcl-2. | 39, 179 |
| Dopaminergic neuronal cell line [(1RB3AN27(N27)] and Parkinson's animal model.       | Concentration of 20, 50 or 100 μM curcumin for 24 hours on cortical neurons or doses of 10-50 mg / kg in Parkinson’s animal model. | Curcumin significantly decreased GSSG, lipid peroxidation, ROS, H2O2 and increased GSH and inhibited cell death.                                                                                                               | 180 and 192 |
| Neuronal Cell Culture (Human SK-N-SH) and Animal Model (athymic) Alzheimer's Disease | Concentrations of 250 nM, 500 nM, 1 M, 2.5 M, and 5 M curcumin for 48 hours on cell culture and doses of 25 mg / kg administered intraperitoneally for 4-6 weeks for animals. | Curcumin decreased lactate dehydrogenase, lipid peroxidation, ROS, H2O2 and inhibited Caspase 3 and 9 and increased cell density.                                                                                             | 181  |
| Rat model of cognitive defect by homocysteine                                         | Curcumin treatments were performed for 10 days as 5,15 and 45 mg /kg, gavage | Increases in neurogenesis and memory recognition, and decreases in lipid peroxidation and anion superoxide.                                                                                                                      | 88 and 182 |
| Animal model of neurotoxicity induced by fluoride                                     | Doses of 10 and 20 mg /kg and 30 mg /kg for 2 weeks.       | Curcumin improves nerve damage and reduces lipid peroxidation.                                                                                                                                                                                                                       | 183  |
| Rat model of sporadic dementia of Alzheimer's type (SDAT)                            | Doses of 80 mg /kg for three weeks.                       | Curcumin decreased (MDA), thiobarbituric reactive substances, hydrogen peroxide, protein carbonyl, and GSSG; increased levels of GSH and its dependent enzymes (Glutathione peroxidase, glutathione reductase, and increased activity of choline acetyltransferase (ChAT). | 184  |
| Animals model of ketamine-induced mania (rat).                                        | Doses of 20 and 50 mg / kg curcumin for 14 days i.p.      | Improved behavioral dysfunction and increased Catalase, Superoxide dismutase and decreased Thiobarbituric acid reactive species formation                                                                                                                                       | 185  |
| Animal models of nicotine morphine and alcohol induced neurotoxicity                 | Doses of 10, 20, 40 and 60 mg / kg curcumin for 21 days i.p in nicotine or alcohol-dependent rat | Decreased nicotine and/or induced apoptosis, oxidative stress and inflammation and increased levels of P-CREB and BDNF. Curcumin also decreased prostaglandin levels E(1), E(2), F(2alpha) and D(2) in rats treated with alcohol. | 45,46, 47 and 187 |
| Animal model of cerebral ischemia(rat)                                               | Treatment of Curcumin (200 mg / kg / day, i.p.) at three different times (immediately, 3 hours and 24 hours after ischemia) | Reduced dead cells and biomarkers of apoptosis in cortex and also decreased oxidative stress biomarkers.                                                                                                                                             | 189  |
Curcumin and neuroprotection

| Description                                                        | Details                                                                                                                                                                                                 | Page |
|-------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| Cortical neuron of the animal that induced excitotoxicity by glutamate | Concentrations of 0, 1.26, 2.6, 6 and 10μM curcumin for 24 hours on cortical neurons                                                                                                                     | 58   |
| Animal model of corticosterone induced depression (rat)            | Doses of 5, 10, 20 and 10μM curcumin for 3 weeks.                                                                                                                                                     | 190  |
| Animal model of cerebral ischemia reperfusion (rat)               | Rats were pre-treated with either a low (50 mg / kg, intraperitoneal injection) or a high (100 mg / kg, intraperitoneal injection) curcumin dose for 5 days.                                                  | 194  |
| Animal model of focal cerebral ischemia-reperfusion (rat)         | Doses of 100 mg/kg and 300 mg/kg.                                                                                                                                                                      | 72, 50 and 192 |
| Cell culture from animal model of brain injury (rat)              | Curcumin concentrations (2.5, 5.0, 10 and 25 mM) after 1 hour of brain injury.                                                                                                                      | 196  |
| Cerebral artery occlusion induced focal cerebral ischemia in rats | Curcumin administered 100 and 300 mg / kg, i.p. 30 minutes after the occlusion of the cerebral artery                                                                                                   | 197  |
| Animal model of Gulf War Illness in rat                           | Curcumin treatment for 30 days                                                                                                                                                                        | 154  |
| Animal model of diabetic rat                                      | Curcumin (100 mg / kg b.w.) was administered to the diabetic group after induction and for eight weeks.                                                                                               | 199  |

Curcumin inhibits apoptosis in glutamate-induced cell death and up regulates BDNF and TrkB expression
Curcumin inhibits oxidative stress and cell death, and up-regulates BDNF and TrkB expression and confers antidepressants.
Increased mitochondrial uncoupling protein 2 and increased mitochondrial biogenesis. Nuclear factor-erythroid 2-related factor 2 (Nrf2) to the antioxidant response element (ARE) has also been increased.
Curcumin improves the symptoms of nerve damage and infarction volume and reduces the water content of the brain and relieves neuronal apoptosis (Bax level) and also increases the expression of p MEK, p ERK, p CREB, Bcl 2. Alos reduces lipid peroxidation and increases superoxide dismutase.
Curcumin inhibits cell degeneration, lactate dehydrogenase, volume of infarction and inhibits cell death. Activate the Akt / Nrf2 pathway in the treated rat.
Increase the activity of superoxide dismutase, glutathione peroxide and decrease lipid peroxidation and peroxynitrite.
Enhanced neurogenesis, restrained inflammation and oxidative stress with normalized mitochondrial respiration.
Curcumin significantly improved blood glucose level, redox status, cellular stress, and decreased INF-γ and Bax levels, down-regulated GRP78 and ATF-4 expression, meanwhile, up-regulated Bcl2 and ChAT expression in the hippocampus.

involved neurogenesis transcription factors, and inhibit neurotoxicity (207). As a result, curcumin therapy rapidly induces an increase in activating Akt-Ser473 phosphorylation, and exerts inhibitory effects on GSK3β phosphorylation, as well as an increase in activating CREB- Ser133 phosphorylation, two mechanisms known to control peroxisome proliferator- activated receptor gamma coactivator 1-alpha (PGC-1α) expression (164, 194, 208). PGC-1α expression may be involved in the neuroprotective role of curcumin (208). Taken together, the results suggest that curcumin induces mitochondrial biogenesis via Akt/GSK3 or Akt/CREB/PGC-1α cascades, which elucidates the
pleiotropic effects of curcumin, and also reveals novel beneficial effects through the preservation of mitochondrial functions (164, 194, 208, 209). Another study suggested that curcumin can modulate GSK3β in neurodegenerative animal models; GSK3β regulates mitochondrial energy metabolism (209). Consequently, inhibition of GSK3β in mice in vivo alters the metabolism of the hippocampus. This work shows that inhibition of GSK3β increases the mitochondrial respiration and membrane potential, and alters NAD(P)H metabolism (210). These metabolic effects are associated with increased stabilization of the PGC-1α proteins, increased nuclear localization, and increased transcriptional co-activation (210). Alteration of the hippocampal energy metabolism is correlated with increasing Pgc-1α in mice treated with the GSK3β inhibitor curcumin. These data indicate that curcumin has a metabolic effect on brain GSK3β. In addition, it can be concluded that GSK3β/PGC-1α axis may be essential in the metabolic integrity of the neurons leading to neuroprotection (193, 210, 211). Complex I (NADH dehydrogenase) and complex IV (cytochrome-c-oxidase) of the mitochondrial electron transport chain have been reported to be affected by drugs used to treat psychiatric or neurodegenerative diseases, including antidepressants, antipsychotics, anxiolytics, mood stabilizers, stimulants, anti-dementia, and anti-parkinsonian drugs. Recent data on the effects of curcumin on complex I and IV have been conducted. These studies assessed complex I and IV enzyme activity levels in the rodents brain, and revealed that curcumin increases complexes I and IV, which contribute to neural cell defense against neurodegenerative agents or events (22, 23, 52, 84, 211, 212). Taken together, these results indicate that curcumin could be a good alternative in the neurodegeneration to prevent or decrease nitrosative and oxidative stress as well as mitochondrial dysfunction. Therefore, in subjects suffering from neurodegeneration, curcumin may be useful for the prevention and/or treatment of oxidative stress and mitochondrial dysfunction.

**Involvement of PI3/Akt/ GSK3 or PI3/Akt/CREB/BDNF signaling pathways**

As described above, the mechanism of curcumin neuroprotection is introduced by its anti-oxidant, anti-inflammatory, and anti-apoptotic system, which is mediated by two significant signaling pathways, PI3/Akt/GSK3 or PI3/Akt/CREB/BDNF (160, 164, 194, 213). Previous studies have shown that phosphatidylinositol 3-kinase (PI3K) activation (phosphorylation) of protein kinase B (Akt) results in Akt activation that may trigger neurodegenerative event inhibition (57, 214). GSK3β protein is an important biomarker for neurodegenerative diseases (215). Previous studies have shown that activation of GSK3β proteins (hyper-phosphorylation) by reduced activity of Akt causes toxic effects due to accumulation within cells (216, 217). According to previous studies, the reduction of Akt and thus the accumulation of hyper-phosphorylated GSK3β in neural cells causes mitochondrial dysfunction, and leads to neurotoxicity (218). According to previous studies, the reduction of Akt and thus accumulation of hyper-phosphorylated GSK3β in neural cells causes mitochondrial dysfunction and leads to neurotoxicity (218, 219). Many previous studies have shown that curcumin acts by activation of Akt and thus causes GSK3β hypo-phosphorylation in neural cells, leading to cell survival and protection against degenerative events (213, 220, 221). Given the importance of the PI3/Akt/GSK signaling pathway in the neuroprotective process of curcumin, this signaling pathway seems to mediate curcumin-induced neuroprotection and mitochondrial biogenesis (by regulation of oxidative stress, inflammation, and apoptosis) and behavioral disturbances. According to the above statement, GSK-3 can be considered as a significant
way of mediating the neuroprotective effects of curcumin on major systems such as antioxidant, anti-apoptosis, and anti-inflammation by suppressing the development of IL-6 and the activation of astrocytes (79, 209, 222). PI3/Akt/GSK signaling pathway plays a crucial role on the neurobehavioral effects of curcumin, and is involved in the antidepressant and anxiolytic effects of curcumin (223-229). Curcumin has also been shown to regulate PI3/Akt/GSK3 not only directly but also through more complex network effects and downstream pathways affecting more than one serial molecular target signal (160). Significant correlation with PI3/Akt/GSK3 signaling and curcumin activation of events involving neurogenesis needs to be further evaluated. This could lead to the development of an understanding of the role of curcumin and the development of this agent as a new generation of neuroprotective combination with a clear mechanism of action and a signaling pathway.

Another signaling pathway that is essential in the effects of curcumin on brain cells is PI3/Akt/CREB/BDNF (158, 160). Activation (phosphorylation) of PI3K followed by Akt phosphorylation causes activation (phosphorylation) of CREB which leads to BDNF synthesis (230, 231). During brain development and neurogenesis, CREB functions as a major transcription factor (231). CREB is activated in a phosphorylated state and several protein kinases in particular Akt phosphorylate this transcription factor, and transform CREB into its active form (232). CREB acts on DNA and promotes the production of BDNF protein which is important in neurogenesis and neuronal development (233). In addition, several previous studies have found that the neuroprotective effect of curcumin could be mediated by triggering the PI3/Akt/CREB/BDNF pathway and by this mechanism, encouraging cell survival and disrupting neurodegeneration cascades (28, 100, 160). Curcumin also inhibited pro-apoptotic molecules such as p53 and Bax by activation of PI3/Akt/CREB/BDNF (45). Curcumin pretreatment by modulation of PI3/Akt/CREB/BDNF inhibited the release of glutamate-induced mitochondrial cytochrome c, activation of caspase-3, and cleavage of lamin B1, the nuclear substrate for caspase-3, a crucial enzyme that mediates apoptosis (40, 41). Acute exposure to curcumin also protected cortical neurons through PI3/Akt/CREB/BDNF and significantly reduced pro-inflammatory biomarkers (IFN-α, TNF-α, IL-8) and increased anti-inflammatory cytokines/compounds (IL-10, IL-1) (141, 143, 149). Strong association with PI3/Akt/CREB/BDNF signaling and curcumin neuroprotection offers further insight into the use of this agent in neurodegenerative events as a potent neuroprotective.

It should be noted that in the current review, PI3/Akt/BDNF and PI3/Akt/GSK3 signaling pathway was chosen for assessment, explanation and association of this signaling pathway with antioxidant, anti-inflammatory and anti-apoptosis effects of curcumin. The explanation for this choice is that there are many evidence on the role of these two signaling pathway impacts on neuroprotective and neurobehavioral effects of curcumin, and this has allowed us to better evaluate the neuroprotective efficacy of curcumin in both molecular and behavioral aspects. Therefore, we based this review on the mentioned signaling pathways and their association with antioxidant, anti-inflammatory, and anti-apoptotic effects of curcumin. Although there are some less important other signaling pathways proposed for the neuroprotective effects of curcumin in the literature to date, some parts of this signaling pathway include Akt/Nrf2 (nuclear factor-erythroid 2-related factor 2) which is essential in the neuroprotective effects of curcumin in hypoxia-induced oxidative damages (47, 194); TLR2/4-NF-B (toll-like receptors type 2 and 4/nuclear factor-B) which is
important in the anti-inflammatory and immunomodulatory role of curcumin in brain cells (42); janus kinases (JAKs)/signal transducer and transcription protein activator (STATs), JAK2/STAT3, involving neuroprotective effects of curcumin inflammatory process during hypoxia induced neural cell damages (234); Nrf2-ARE (antioxidant responsive element) signaling pathways involving curcumin ability to increase the activity of antioxidant enzymes and attenuation of brain injury in the traumatic brain injury model (235); Wnt/β-catenin signaling pathways involving curcumin antioxidant effects against oxidative stress-induced injury in some neurodegenerative disease (236). In terms of the amount of data available on this miscellaneous signaling pathway and their role in curcumin neuroprotective effects, there was less information compared to PI3/Akt/CREB/BDNF and PI3/Akt/GSK3 signaling pathways, and therefore we tried to focus our assessment on these two pathways. Given the importance of these two signaling pathways, they could provide useful clues for researchers to further assessing the effects of curcumin and its neuroprotective role, as these two signaling pathways known as two key highways between all signaling pathways and routes have a crucial role in comparison to other signaling pathways, and most neuroprotective agents (both herbal and synthetic) confer neuroprotective activity through these signaling pathways. It can therefore be suggested that PI3/Akt/CREB/BDNF and PI3/Akt/GSK3 signaling pathways have a high potential to be the target for modulation of oxidative stress, apoptosis and inflammation, cognition and mood-related disorders after curcumin administration, which may ultimately result in neuroprotection against neurodegenerative disorders or diseases. Thus, PI3/Akt/CREB/BDNF and PI3/Akt/GSK3 signaling pathways have a high potential for targeting drug therapy and design in human studies phases.

**Conclusion**

The neuroprotective effects of curcumin are based on the fact that it modulates several homeostatic mechanisms involved in neurotrophic response, autophagy, oxidative stress, inflammation and mitochondrial function, in particular through PI3/Akt/GSK3 or PI3/Akt/CREB/BDNF signaling pathways (Figure-5). In the present review, we reviewed a number of experimental and clinical studies focusing on the neurobiological properties and underlying mechanism of curcumin in the light of available evidence of its neurotrophic and neuroprotective properties. The current review also gathered new investigations on the mediation of PI3/Akt/GSK3 or PI3/Akt/CREB/BDNF signaling pathways for neuroprotective curcumin properties. Taken together, these findings provide a strong rationale for exploring curcumin as a potential treatment for neurodegenerative diseases.

**References**

1. Andreone BJ, Larhammar M, Lewcock JW. Cell Death and Neurodegeneration. Cold Spring Harb Perspect Biol 2020;12.
2. Irwin MH, Moos WH, Faller DV, et al. Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases. Drug Dev Res 2016;77:109-23.
3. Cole GM, Teter B, Frautschy SA. Neuroprotective effects of curcumin. Adv Exp Med Biol 2007;595:197-212.
4. Vajda FI. Neuroprotection and neurodegenerative disease. J Clin Neurosci 2002;9:4-8.
5. Akwa Y, Allain H, Bentue-Ferrer D, et al. Neuroprotection and neurodegenerative diseases: from biology to clinical practice. Alzheimer Dis Assoc Disord 2005;19:226-39.
6. Chiba T, Nishimoto I, Aiso S, et al. Neuroprotection against neurodegenerative diseases: development of a novel hybrid neuroprotective peptide Colivelin. Mol Neurobiol 2007;35:55-84.
7. Darvesh AS, Carroll RT, Bishayee A, et al. Curcumin and neurodegenerative diseases: a perspective. Expert Opin Investig Drugs 2012;21:1123-40.
8. Pulido-Moran M, Moreno-Fernandez J, Ramirez-Tortosa C, et al. Curcumin and Health. Molecules 2016;21:264.
Curcumin and neuroprotection

9. Hewlings SJ, Kalman DS. Curcumin: A Review of Its’ Effects on Human Health. Foods 2017;6.
10. Barve S, Chen SY, Kirpich I, et al. Development, Prevention, and Treatment of Alcohol-Induced Organ Injury: The Role of Nutrition. Alcohol Res 2017;38:289-302.
11. Whitman IR, Agarwal V, Nah G, et al. Alcohol Abuse and Cardiac Disease. J Am Coll Cardiol 2017;69:13-24.
12. Zakhar S, Li TK. Determinants of alcohol use and abuse: Impact of quantity and frequency patterns on liver disease. Hepatology 2007;46:2032-9.
13. Monroy A, Lithgow GI, Alavez S. Curcumin and neurodegenerative diseases. Biofactors 2013;39:122-32.
14. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 2009;41:40-59.
15. Scapagnini G, Colombrita C, Amadio M, et al. Curcumin activates defensive genes and protects neurons against oxidative stress. Antioxid Redox Signal 2006;8:395-403.
16. Dong S, Zeng Q, Mitchell ES, et al. Curcumin enhances neurogenesis and cognition in aged rats: implications for transcriptional interactions related to growth and synaptic plasticity. PLoS One 2012;7:e31211.
17. Hamaguchi T, Ono K, Yamada M. REVIEW: Curcumin and Alzheimer's disease. CNS Neurosci Ther 2010;16:285-97.
18. Chin D, Huebbe P, Pallauf K, et al. Neuroprotective properties of curcumin in Alzheimer's disease—merits and limitations. Curr Med Chem 2013;20:3955-85.
19. Chaturvedi RK, Beal MF. Mitochondrial approaches for neuroprotection. Ann N Y Acad Sci 2008;1147:395-412.
20. Van Giu V, An SSA, Hulme JP. Mitochondrial therapeutic interventions in Alzheimer's disease. J Neurol Sci 2018;395:62-70.
21. Naoi M, Wu Y, Shamoto-Nagai M, et al. Mitochondria in Neuroprotection by Phytochemicals: Bioactive Polyphenols Modulate Mitochondrial Apoptosis System, Function and Structure. Int J Mol Sci 2019;20:20.
22. Hagl S, Kocher A, Schiborr C, et al. Curcumin micelles improve mitochondrial function in neuronal PC12 cells and brains of NMRI mice - Impact on bioavailability. Neurochem Int 2015;89:234-42.
23. Eckert GP, Schiborr C, Hagl S, et al. Curcumin prevents mitochondrial dysfunction in the brain of the senescence-accelerated mouse-prone 8. Neurochem Int 2013;62:595-602.
24. Davey A, Agrawal SK. Curcumin alleviates oxidative stress and mitochondrial dysfunction in astrocytes. Neuroscience 2016;333:92-103.
25. de Oliveira MR, Jardim FR, Setzer WN, et al. Curcumin, mitochondrial biogenesis, and mitophagy: Exploring recent data and indicating future needs. Biotechnol Adv 2016;34:813-26.
26. Bagheri H, Ghasemi F, Barreto GE, et al. Effects of curcumin on mitochondria in neurodegenerative diseases. Biofactors 2020;46:5-20.
27. Abdollahi E, Montaza AA, Johnston TP, et al. Therapeutic effects of curcumin in inflammatory and immune-mediated diseases: A nature-made jack-of-all-trades? J Cell Physiol 2018;233:830-48.
28. Balasubramanyam K, Varier RA, Altaf M, et al. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 2004;279:51163-71.
29. Bhat A, Mahalakshmi AM, Ray B, et al. Benefits of curcumin in brain disorders. Biofactors 2019;45:666-89.
30. Brondino N, Re S, Boldrini A, et al. Curcumin as a therapeutic agent in dementia: a mini systematic review of human studies. ScientificWorldJournal 2014;2014:174282.
31. Epstein J, Sanderson IR, Macdonald TT. Curcumin as a therapeutic agent in dementia: the evidence from in vitro, animal and human studies. Br J Nutr 2010;103:1545-57.
32. Mishra S, Palanivelu K. The effect of curcumin (turmeric) on Alzheimer's disease: An overview. Ann Indian Acad Neur 2008;11:13-9.
33. Veldman ER, Jia Z, Halldin C, et al. Amyloid binding properties of curcumin analogues in Alzheimer's disease postmortem brain tissue. Neurosci Lett 2016;630:183-8.
34. Gokce EC, Kahveci R, Gokce A, et al. Curcumin Attenuates Inflammation, Oxidative Stress, and Ultrastructural Damage Induced by Spinal Cord Ischemia-Reperfusion Injury in Rats. J Stroke Cerebrovasc Dis 2016;25:1196-207.
35. Yang J, Song S, Li J, et al. Neuroprotective effect of curcumin on hippocampal injury in 6-OHDA-induced Parkinson’s disease rat. Pathol Res Pract 2014;210:357-62.
36. Kulkarni S, Dhir A, Akula KK. Potentials of curcumin as an antidepressant. Scientific World Journal 2009;9:1233-41.
37. Chiu TL, Su CC. Curcumin inhibits proliferation and migration by increasing the Bax to Bcl-2 ratio and decreasing NF-kappaBp65 expression in breast cancer MDA-MB-231 cells. Int J Mol Med 2009;23:469-75.
38. Zhu YG, Chen XC, Chen ZZ, et al. Curcumin protects mitochondria from oxidative damage and attenuates apoptosis in cortical neurons. Acta Pharmacol Sin 2004;25:1606-12.
39. Matteucci A, Cammarota R, Paradisi S, et al. Curcumin protects against NMDA-induced toxicity: a possible role for NR2A subunit. Invest Ophthalmol Vis Sci 2011;52:1070-7.
40. Jayanarayanan S, Smijin S, Peeyush KT, et al. NMDA and AMPA receptor mediated excitotoxicity in cerebral cortex of streptozotocin induced diabetic rat: ameliorating effects of curcumin. Chem Biol Interact 2013;201:39-48.
41. Zhang L, Xu T, Wang S, et al. NMDA GluN2B receptors involved in the antidepressant effects of curcumin in the forced swim test. Prog Neuropsychopharmacol Biol Psychiatry 2013;40:12-7.
42. Zhu HT, Bian C, Yuan JC, et al. Curcumin attenuates acute inflammatory injury by inhibiting the TLR4/MyD88/NF-kappaB signaling pathway in experimental traumatic brain injury. J Neuroinflammation 2014;11:59.
43. Soetikno V, Sari FR, Sukumaran V, et al. Curcumin prevents diabetic cardiomyopathy in streptozotocin-induced diabetic rats: possible involvement of PKC-MAPK signaling pathway. Eur J Pharm Sci 2012;47:604-14.
44. Motaghipanah M, Motevalian M, Fatima S, et al. The Neuroprotective Effect of Curcumin Against Nicotine-Induced Neurotoxicity is Mediated by CREB-BDNF Signaling Pathway. Neurochem Res 2017;42:2921-32.
45. Motaghipanah M, Karimian M, Motaghipanah O, et al. Protective effects of various dosage of Curcumin against morphine induced apoptosis and oxidative stress in rat isolated hippocampus. Pharmacol Rep 2015;67:230-5.
46. Motaghipanah M, Motevalian M, Fatima S, et al. Curcumin confers neuroprotection against alcohol-induced hippocampal neurodegeneration via CREB-BDNF pathway in rats. Biomed Pharmacother 2017;87:721-40.
47. Yang C, Zhang X, Fan H, et al. Curcumin upregulates transcription factor Nrf2, HO-1 expression and protects rat brains against focal ischemia. Brain Res 2009;1282:133-41.
48. Jiang J, Wang W, Sun YJ, et al. Neuroprotective effect of curcumin on focal cerebral ischemic rats by preventing blood-brain barrier damage. Eur J Pharmaco 2007;561:54-62.
49. Shukla PK, Khanna VK, Ali MM, et al. Anti-ischemic effect of curcumin in rat brain. Neurochem Res 2008;33:1036-43.
50. Vera-Ramirez L, Perez-Lopez P, Varela-Lopez A, et al. Curcumin and liver disease. Biofactors 2013;39:88-100.
51. Pari L, Tewas D, Eckel J. Role of curcumin in health and disease. Arch Physiol Biochem 2008;114:127-49.
52. Ligeret H, Barthelemy S, Zini R, et al. Effects of curcumin and curcumin derivatives on mitochondrial permeability transition pore. Free Radic Biol Med 2004;36:919-29.
53. Zhang J, Xu L, Zhang L, et al. Curcumin attenuates D-galactosamine/hypopolysaccharide-induced liver injury and mitochondrial dysfunction in mice. J Nutr 2014;144:1211-8.
54. Fu Y, Zheng S, Lin J, et al. Curcumin protects the rat liver from CCI4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. Mol Pharmacol 2008;73:399-409.
55. Reyes-Gordillo K, Segovia J, Shibayama M, et al. Curcumin protects against acute liver damage in the rat by inhibiting NF-kappaB, proinflammatory cytokines production and oxidative stress. Biofactors 2013;39:1240-9.
56. Chen J, Tang XQ, Zhi JL, et al. Curcumin protects PC12 cells against 1-methyl-4-phenylpyridinium ion-induced apoptosis by bcl-2-mitochondria-ROS-iNOS pathway. Apoptosis 2006;11:943-53.
57. Wang R, Li YB, Li YH, et al. Curcumin protects against glutamate excitotoxicity in rat cerebral cortical neurons by increasing brain-derived neurotrophic factor level and activating TrkB. Brain Res 2008;1210:84-91.
58. Wei S, Xu H, Xia D, et al. Curcumin attenuates the effects of transport stress on serum cortisol concentrations, hippocampal NO production, and BDNF expression in the pig. Domest Anim Endocrinol 2010;39:231-9.
59. Keskin-Aktan A, Akbulut KG, Yazici-Mutlu C, et al. The effects of melatonin and curcumin on the expression of SIRT2, Bcl-2 and Bax in the hippocampus of adult rats. Brain Res Bull 2018;137:306-10.
Curcumin and neuroprotection

60. Hu S, Maiti P, Ma Q, et al. Clinical development of curcumin in neurodegenerative disease. Expert Rev Neurother 2015;15:629-37.

61. Maheshwari RK, Singh AK, Gaddipati J, et al. Multiple biological activities of curcumin: a short review. Life Sci 2006;78:2081-7.

62. Noorafshan A, Ashkani-Esfahani S. A review of therapeutic effects of curcumin. Curr Pharm Des 2013;19:2032-46.

63. Ali BH, Marrif H, Noureldayem SA, et al. Some biological properties of curcumin: A review. Nat Prod Commun 2006;1:509-21.

64. Motaghinejad M, Bangash MY, Hosseini P, et al. Attenuation of morphine withdrawal syndrome by various dosages of curcumin in comparison with clonidine in mouse: possible mechanism. Iran J Med Sci 2015;40:125-32.

65. Roth KA, D'Sa C. Apoptosis and brain development. Ment Retard Dev Disabil Res Rev 2001;7:261-6.

66. Bieberich E, MacKinnon S, Silva J, et al. Regulation of apoptosis during neuronal differentiation by ceramide and b-series complex gangliosides. J Biol Chem 2001;276:44396-404.

67. Loh KP, Huang SH, De Silva R, et al. Oxidative stress: apoptosis in neuronal injury. Curr Alzheimer Res 2006;3:327-37.

68. Zhao J, Zhao Y, Zheng W, et al. Neuroprotective effect of curcumin on transient focal cerebral ischemia in rats. Brain Res 2008;1229:224-32.

69. Shehzad A, Islam SUl, Lee YS. Curcumin and Inflammatory Brain Diseases. Curcumin for Neurological and Psychiatric Disorders: Elsevier; 2019. p. 437.

70. Dong W, Yang B, Wang L, et al. Curcumin plays neuroprotective roles against traumatic brain injury partly via Nrf2 signaling. Toxicol Appl Pharmacol 2018;346:28-36.

71. Xu L, Ding L, Su Y, et al. Neuroprotective effects of curcumin against rats with focal cerebral ischemia-reperfusion injury. Int J Mol Med 2019;43:1879-87.

72. Yu Z, Wan Y, Liu Y, et al. Curcumin induced apoptosis via PI3K/Akt-signalling pathways in SKOV3 cells. Pharm Biol 2016;54:2026-32.

73. Thompson AG, Gray E, Heman-Ackah SM, et al. Extracellular vesicles in neurodegenerative disease - pathogenesis to biomarkers. Nat Rev Neurol 2016;12:346-57.

74. Shabab T, Khanabdali R, Moghadamtousi SZ, et al. Neuroinflammation pathways: a general review. Int J Neurosci 2017;127:624-33.

75. Leo EEM, Campos MRS. Systemic Oxidative Stress: A Key Point in Neurodegeneration—A Review. J Nutr Health Aging 2019;23:694-9.

76. Soudier DC, Anderson RM. An expanding GSK3 network: implications for aging research. GeroScience 2019;41:369-82.

77. Motaghinejad M, Motevalian M, Fatima S, et al. Topiramate via NMDA, AMPA/kainate, GABAA and Alpha2 receptors and by modulation of CREB/BDNF and Akt/GSK3 signaling pathway exerts neuroprotective effects against methylphenidate-induced neurotoxicity in rats. J Neural Transm (Vienna) 2017;124:1369-87.

78. Rahimi Borumand M, Motaghinejad M, Motevalian M, et al. Duloxetine by Modulating the Akt/GSK3 Signaling Pathways Has Neuroprotective Effects against Methamphetamine-Induced Neurodegeneration and Cognition Impairment in Rats. Iran J Med Sci 2019;44:146-54.

79. McCubrey JA, Lerptipiyapong K, Steelman LS, et al. Regulation of GSK-3 activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases. Adv Biol Regul 2017;65:77-88.

80. Sun J, Zhang X, Wang C, et al. Curcumin Decreases Hyperphosphorylation of Tau by Down-Regulating Caveolin-1/GSK-3beta in N2a/APP695swe Cells and APP/PS1 Double Transgenic Alzheimer's Disease Mice. Am J Chin Med 2017;45:1667-82.

81. Attari F, Sharifi ZN, Movassaghi S, et al. Neuroprotective effects of curcumin against transient global ischemia are dose and area dependent. Arch Neurosci 2016;3:e32600.

82. Yu LS, Fan YY, Ye G, et al. Curcumin alleviates brain edema by lowering AQP4 expression levels in a rat model of hypoxia-hypercapnia-induced brain damage. Exp Ther Med 2016;11:709-16.

83. Fu XY, Yang MF, Cao MZ, et al. Strategy to Suppress Oxidative Damage-Induced Neurotoxicity in PC12 Cells by Curcumin: the Role of ROS-Mediated DNA Damage and the MAPK and AKT Pathways. Mol Neurobiol 2016;53:369-78.

84. Banji OJ, Banji D, Ch K. Curcumin and hesperidin improve cognition by suppressing mitochondrial dysfunction and
apoptosis induced by D-galactose in rat brain. Food Chem Toxicol 2014;74:51-9.
85. Voulgaropoulou SD, van Amelsvoort T, Prickaerts J, et al. The effect of curcumin on cognition in Alzheimer’s disease and healthy aging: A systematic review of pre-clinical and clinical studies. Brain Res 2019;1725:146476.
86. Bassani TB, Turnes JM, Moura ELR, et al. Effects of curcumin on short-term spatial and recognition memory, adult neurogenesis and neuroinflammation in a streptozotocin-induced rat model of dementia of Alzheimer’s type. Behav Brain Res 2017;335:41-54.
87. Ataie A, Sabetkasaei M, Haghparast A, et al. Curcumin exerts neuroprotective effects against homocysteine intracerebroventricular injection-induced cognitive impairment and oxidative stress in rat brain. J Med Food 2010;13:821-6.
88. Xie Y, Zhao QY, Li HY, et al. Curcumin ameliorates cognitive deficits heavy ion irradiation-induced learning and memory deficits through enhancing of Nrf2 antioxidant signaling pathways. Pharmacol Biochem Behav 2014;126:181-6.
89. Noguchi-Shinohara M, Hamaguchi T, Yamada M. The Potential Role of Curcumin in Treatment and Prevention for Neurological Disorders. Curcumin for Neurological and Psychiatric Disorders: Elsevier; 2019. p. 85-103.
90. Bardak H, Uguz AC, Bardak Y. Curcumin regulates intracellular calcium release and inhibits oxidative stress parameters, VEGF, and caspase-3/-9 levels in human retinal pigment epithelium cells. Physiol Int 2017;104:301-15.
91. Uguz AC, Oz A, Naziroglu M. Curcumin inhibits apoptosis by regulating intracellular calcium release, reactive oxygen species and mitochondrial depolarization levels in SH-SY5Y neuronal cells. J Recept Signal Transduct Res 2016;36:395-401.
92. ÖZ A, Çelik Ö, Övey İS. Effects of different doses of curcumin on apoptosis, mitochondrial oxidative stress and calcium influx in DBTRG glioblastoma cells. Journal of Cellular Neuroscience & Oxidative Stress 2017;9.
93. Mallozzi C, Parravano M, Gaddini L, et al. Curcumin Modulates the NMDA Receptor Subunit Composition Through a Mechanism Involving CaMKII and Ser/Thr Protein Phosphatases. Cell Mol Neurobiol 2018;38:1315-20.
94. Kaur A, Kaur T, Singh B, et al. Curcumin alleviates ischemia reperfusion-induced acute kidney injury through NMDA receptor antagonism in rats. Ren Fail 2016;38:1462-7.
95. Hussain AR, Al-Rasheed M, Manogaran PS, et al. Curcumin induces apoptosis via inhibition of PI3'-kinase/AKT pathway in acute T cell leukemias. Apoptosis 2006;11:245-54.
96. Squares MS, Hudson EA, Howells L, et al. Relevance of mitogen activated protein kinase (MAPK) and phosphotyidinositol-3-kinase/protein kinase B (PI3K/PKB) pathways to induction of apoptosis by curcumin in breast cells. Biochem Pharmacol 2003;65:361-76.
97. Radhakrishna Pillai G, Srivastava AS, Hassanein TI, et al. Induction of apoptosis in human lung cancer cells by curcumin. Cancer Lett 2004;208:163-70.
98. Shi M, Cai Q, Yao L, et al. Antiproliferation and apoptosis induced by curcumin in human ovarian cancer cells. Cell Biol Int 2006;30:221-6.
99. Xu Y, Ku B, Cui L, et al. Curcumin reverses impaired hippocampal neurogenesis and increases serotonin receptor 1A mRNA and brain-derived neurotrophic factor expression in chronically stressed rats. Brain Res 2007;1162:9-18.
100. Xu Y, Ku B, Tie L, et al. Curcumin reverses the effects of chronic stress on behavior, the HPA axis, BDNF expression and phosphorylation of CREB. Brain Res 2006;1122:56-64.
101. Kumar TP, Antony S, Gireesh G, et al. Curcumin modulates dopaminergic receptor, CREB and phospholipase C gene expression in the cerebral cortex and cerebellum of streptozotocin induced diabetic rats. J Biomed Sci 2010;17:43.
102. Zhang L, Xu T, Wang S, et al. Curcumin produces antidepressant effects via activating MAPK/ERK-dependent brain-derived neurotrophic factor expression in the amygdala of mice. Behav Brain Res 2012;235:67-72.
103. Zhang L, Fang Y, Xu Y, et al. Curcumin Improves Amyloid beta-Peptide (1-42) Induced Spatial Memory Deficits through BDNF-ERK Signaling Pathway. PLoS One 2015;10:e0131525.
104. Pluta R, Bogucka-Kocka A, Ulamek-Koziol M, et al. Neurogenesis and neuroprotection in postischemic brain neurodegeneration with Alzheimer phenotype: is there a role for curcumin? Folia Neuropathol 2015;53:89-99.
105. Seo HJ, Wang SM, Han C, et al. Curcumin as a putative antidepressant. Expert Rev Neurother 2015;15:269-80.
106. Vivar C. Adult Hippocampal Neurogenesis, Aging and Neurodegenerative Diseases: Possible Strategies to Prevent Cognitive Impairment. Curr Top Med Chem 2015;15:2175-92.
107. Kim SJ, Son TG, Park HR, et al. Curcumin stimulates...
Curcumin and neuroprotection

proliferation of embryonic neural progenitor cells and neurogenesis in the adult hippocampus. J Biol Chem 2008;283:14497-505.

108. Kang SK, Cha SH, Jeon HG. Curcumin-induced histone hypoacetylation enhances caspase-3-dependent glioma cell death and neurogenesis of neural progenitor cells. Stem Cells Dev 2006;15:165-74.

109. Son S, Kim KT, Cho DC, et al. Curcumin Stimulates Proliferation of Spinal Cord Neural Progenitor Cells via a Mitogen-Activated Protein Kinase Signaling Pathway. J Korean Neurosurg Soc 2014;56:1-4.

110. Attari F, Zahmatkesh M, Aligholi H, et al. Curcumin as a double-edged sword for stem cells: dose, time and cell type-specific responses to curcumin. Daru 2015;23:33.

111. Gopal PK, Paul M, Paul S. Curcumin induces caspase mediated apoptosis in JURKAT cells by disrupting the redox balance. Asian Pac J Cancer Prev 2014;15:93-100.

112. Karmakar S, Banik NL, Ray SK. Curcumin suppressed anti-apoptotic signals and activated cysteine proteases for apoptosis in human malignant glioblastoma U87MG cells. Neurochem Res 2007;32:2103-13.

113. Li Y, Li J, Li S, et al. Curcumin attenuates glutamate neurotoxicity in the hippocampus by suppression of ER stress-associated TXNIP/NLRP3 inflammasome activation in a manner dependent on AMPK. Toxicol Appl Pharmacol 2015;286:53-63.

114. Wang J, Liu Y, Li XH, et al. Curcumin protects neuronal cells against status-epilepticus-induced hippocampal damage through induction of autophagy and inhibition of necroptosis. Can J Physiol Pharmacol 2017;95:501-9.

115. Yanagisawa D, Shirai N, Amatsuho T, et al. Binding form of curcumin derivatives to β-amyloid aggregates. Alzheimer's Dement 2009;5:342-3.

116. Reuter S, Eiff E, Sicato M, et al. Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem Pharmacol 2008;76:1340-51.

117. Glass CK, Saijo K, Winner B, et al. Mechanisms underlying inflammation in neurodegeneration. Cell 2010;140:918-34.

118. Perry VH, Cunningham C, Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol 2007;7:161-7.
skin through suppression of extracellular signal-regulated kinase activity and NF-kappaB activation. Carcinogenesis 2003;24:1515-24.

132. Su CC, Chen GW, Lin JG, et al. Curcumin inhibits cell migration of human colon cancer colo 205 cells through the inhibition of nuclear factor kappa B /p65 and down-regulates cyclooxygenase-2 and matrix metalloproteinase-2 expressions. Anticancer Res 2006;26:1281-8.

133. Hong J, Bose M, Ju J, et al. Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase. Carcinogenesis 2004;25:1671-9.

134. Yu L, Yi J, Ye G, et al. Effects of curcumin on levels of nitric oxide synthase and AQP-4 in a rat model of hypoxia-ischemic brain damage. Brain Res 2012;1475:88-95.

135. Yu SY, Gao R, Zhang L, et al. Curcumin ameliorates ethanol-induced memory deficits and enhanced brain nitric oxide synthase activity in mice. Prog Neuropsychopharmacol Biol Psychiatry 2013;44:210-6.

136. Sharma S, Chopra K, Kulkarni SK. Effect of insulin and its combination with resveratrol or curcumin in attenuation of diabetic neuropathic pain: participation of nitric oxide and TNF-alpha. Phytother Res 2007;21:278-83.

137. Kulikarni SK, Dhir A. An overview of curcumin in neurological disorders. Indian J Pharm Sci 2010;72:149-54.

138. Srivastava RM, Singh S, Dubey SK, et al. Immunomodulatory and therapeutic activity of curcumin. Int Immunopharmacol 2011;11:331-41.

139. Cianciulli A, Calvello R, Porro C, et al. PI3K/Akt signalling pathway plays a crucial role in the anti-inflammatory effects of curcumin in LPS-activated microglia. Int Immunopharmacol 2016;36:282-90.

140. Song MY, Yim JY, Yim JM, et al. Use of curcumin to decrease nitric oxide production during the induction of antitumor responses by IL-2. J Immunother 2011;34:149-64.

141. Fahey AJ, Adrian Robins R, Constantinescu CS. Curcumin modulation of IFN-beta and IL-12 signalling and cytokine induction in human T cells. J Cell Mol Med 2007;11:1129-37.

142. Kempuraj D, Thangavel R, Natteru PA, et al. NeuronInflammation Induces Neurodegeneration. J Neurol Neurosurg Spine 2016;1.

143. Ranjan D, Chen C, Johnston TD, et al. Curcumin inhibits mitogen stimulated lymphocyte proliferation, NFKappaB activation, and IL-2 signaling. J Surg Res 2004;121:171-7.

144. Viviani B, Bartesaghi S, Corsini E, et al. Cytokines role in neurodegenerative events. Toxicol Lett 2004;149:85-9.

145. Myint AM, Kim YK. Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med Hypotheses 2003;61:519-25.

146. Xie L, Li XK, Takahara S. Curcumin has bright prospects for the treatment of multiple sclerosis. Int Immunopharmacol 2011;11:323-30.

147. Cho JW, Lee KS, Kim CW. Curcumin attenuates the expression of IL-1beta, IL-6, and TNF-alpha as well as cyclin E in TNF-alpha-treated HaCaT cells; NF-kappaB and MAPKs as potential upstream targets. Int J Mol Med 2007;19:469-74.

148. Larmonier CB, Uno JK, Lee KM, et al. Limit ed effects of dietary curcumin on Th-1 driven colitis in IL-10 deficient mice suggest an IL-10-dependent mechanism of protection. Am J Physiol Gastrointest Liver Physiol 2008;295:G1079-91.

149. Wolkmer P, Silva CB, Paim FC, et al. Pre-treatment with curcumin modulates acetylcholinesterase activity and proinflammatory cytokines in rats infected with Trypanosoma evansi. Parasitol Int 2013;62:144-9.

150. Liu W, Yuan J, Zhu H, et al. Curcumin reduces brain-infiltrating T lymphocytes after intracerebral hemorrhage in mice. Neurosci Lett 2016;620:74-82.

151. Lee HS, Jung KK, Cho JY, et al. Neuroprotective effect of curcumin is mainly mediated by blockade of microglial cell activation. Pharmazie 2007;62:937-42.

152. Awad AS, El-Sharif AA. Curcumin immune-mediated and anti-apoptotic mechanisms protect against renal ischemia/reperfusion and distant organ induced injuries. Int Immunopharmacol 2011;11:992-6.

153. Kodali M, Hattiangady B, Shetty GA, et al. Curcumin treatment leads to better cognitive and mood function in a model of Gulf War Illness with enhanced neurogenesis, and alleviation of inflammation and mitochondrial dysfunction in the hippocampus. Brain Behav Immun 2018;69:499-514.

154. Gu HF, Li N, Tang YL, et al. Nicotinate-curcumin ameliorates cognitive impairment in diabetic rats by rescuing autophagic flux in CA1 hippocampus. CNS Neurosci Ther 2019;25:430-41.

155. Green HF, Nolan YM. GSK-3 mediates the release of IL-
Curcumin and neuroprotection

1-beta, TNF-alpha and IL-10 from cortical glia. Neurochem Int 2012;61:666-71.

156. Hoeflich KP, Luo J, Rubie EA, et al. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000;406:86-90.

157. Ghosh S, Hayden MS. New regulators of NF-kappaB in inflammation. Nat Rev Immunol 2008;8:837-48.

158. Yan D, Yao J, Liu Y, et al. Tau hyperphosphorylation and P-CREB reduction are involved in acrylamide-induced spatial memory impairment: Suppression by curcumin. Brain Behav Immun 2018;71:66-80.

159. Sakamoto K, Karelin K, Obrrietan K. CREB: a multifaceted regulator of neuronal plasticity and protection. J Neurochem 2011;116:1-9.

160. Srivastava P, Dhuriya YK, Kumar V, et al. PI3K/Akt/GSK3beta induced CREB activation ameliorates arsenic mediated alterations in NMDA receptors and associated signaling in rat hippocampus: Neuroprotective role of curcumin. Neurotoxicology 2018;67:190-205.

161. Saydmohammed M, Joseph D, Syed V. Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells. J Cell Biochem 2010;110:447-56.

162. Zu J, Wang Y, Xu G, et al. Curcumin improves the recovery of motor function and reduces spinal cord edema in a rat acute spinal cord injury model by inhibiting the JAK/STAT signaling pathway. Acta Histochem 2014;116:1331-6.

163. Kim HY, Park EJ, Joe EH, et al. Curcumin suppresses Janus kinase-STAT inflammatory signaling through activation of Src homology 2 domain-containing tyrosine phosphatase 2 in brain microglia. J Immunol 2003;171:6072-9.

164. Wang R, Li YH, Xu Y, et al. Curcumin produces neuroprotective effects via activating brain-derived neurotrophic factor/TrkB-dependent MAPK and PI-3K cascades in rodent cortical neurons. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:147-53.

165. Floyd RA. Antioxidants, oxidative stress, and degenerative neurological disorders. Proc Soc Exp Biol Med 1999;222:236-45.

166. Mahadik SP, Evans D, Lai H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:463-93.

167. Machado-Vieira R, Andreazza AC, Viale CI, et al. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett 2007;421:33-6.

168. Yilmaz N, Karaali K, Ozdem S, et al. Elevated S100B and neuron specific enolase levels in patients with migraine-without aura: evidence for neurodegeneration? Cell Mol Neurobiol 2011;31:579-85.

169. Hauge A, Polcyn R, Matzelle D, et al. New Insights into the Role of Neuron-Specific Enolase in Neuro-Inflammation, Neurodegeneration, and Neuroprotection. Brain Sci 2018;8.

170. Andersen JK. Oxidative stress in neurodegeneration: cause or consequence? Nat Med 2004;10 Suppl:S18-25.

171. Schulz JB, Lindenau J, Seyfried J, et al. Glutathione, oxidative stress and neurodegeneration. Eur J Biochem 2000;267:4904-11.

172. Halliwell B. Oxidative stress and neurodegeneration: where are we now? J Neurochem 2006;97:1634-58.

173. Gandhi S, Abramov AV. Mechanism of oxidative stress in neurodegeneration. Oxid Med Cell Longev 2012;2012:12 Page.

174. Shukla V, Mishra SK, Pant HC. Oxidative stress in neurodegeneration. Adv pharmacol sci 2011;2011:14Pages.

175. Schafer M, Goodenough S, Moosmann B, et al. Inhibition of glycogen synthase kinase 3 beta is involved in the resistance to oxidative stress in neuronal HT22 cells. Brain Res 2004;1005:84-9.

176. Yuan G, Adhikary G, McCormick AA, et al. Role of oxidative stress in intermittent hypoxia-induced immediate early gene activation in rat PC12 cells. J Physiol 2004;557:773-83.

177. Cui J, Shao L, Young LT, et al. Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neuroscience 2007;144:1447-53.

178. Lavoie S, Chen Y, Dalton TP, et al. Curcumin, quercetin, and tBHQ modulate glutathione levels in astrocytes and neurons: importance of the glutamate cysteine ligase modifier subunit. J Neurochem 2009;108:1410-22.

179. Harish G, Venkateshappa C, Mythri RB, et al. Bioconjugates of curcumin display improved protection against glutathione depletion mediated oxidative stress in a dopaminergic neuronal cell line: Implications for Parkinson’s disease. Bioorg Med Chem 2010;18:2631-8.
180. Ray B, Bisht S, Maitra A, et al. Neuroprotective and neurorescue effects of a novel polymeric nanoparticle formulation of curcumin (NanoCurc) in the neuronal cell culture and animal model: implications for Alzheimer's disease. J Alzheimers Dis 2011;23:61-77.

181. Ataie A, Sabetkasaei M, Haghpastar A, et al. Neuroprotective effects of the polyphenolic antioxidant agent, Curcumin, against homocysteine-induced cognitive impairment and oxidative stress in the rat. Pharmacol Biochem Behav 2010;96:378-85.

182. Sharma C, Suhalika P, Sukhwal P, et al. Curcumin attenuates neurotoxicity induced by fluoride: An in vivo evidence. Pharmacog Mag 2014;10:61-5.

183. Ishrat T, Hoda MN, Khan MB, et al. Amelioration of cognitive deficits and neurodegeneration by curcumin in rat model of sporadic dementia of Alzheimer's type (SDAT). Eur Neuropsychopharmacol 2009;19:636-47.

184. Gazal M, Valente MR, Acosta BA, et al. Neuroprotective and antioxidant effects of curcumin in a ketamine-induced model of mania in rats. Eur J Pharmacol 2014;724:132-9.

185. Farzaei MH, Zobeiri M, Parvizi F, et al. Curcumin in Liver Diseases: A Systematic Review of the Cellular Mechanisms of Oxidative Stress and Clinical Perspective. Nutrients 2018;10.

186. Rajakrishnan V, Jayadeep A, Arun OS, et al. Changes in the prostaglandin levels in alcohol toxicity: effect of curcumin and N-acetylcysteine. J Nutr Biochem 2000;11:509-14.

187. Shishodia S, Sethi G, Aggarwal BB. Curcumin: getting back to the roots. Ann N Y Acad Sci 2005;1056:206-17.

188. Al-Omar FA, Nagi MN, Abdulgadir MM, et al. Immediate and delayed treatments with curcumin prevents forebrain ischemia-induced neuronal damage and oxidative insult in the rat hippocampus. Neurochem Res 2006;31:611-8.

189. Huang Z, Zhong XM, Li ZY, et al. Curcumin reverses corticosterone-induced depressive-like behavior and decrease in brain BDNF levels in rats. Neurosci Lett 2011;493:145-8.

190. Sharma RA, Steward WP, Gescher AJ. Pharmacokinetics and pharmacodynamics of curcumin. Adv Exp Med Biol 2007;595:453-70.

191. Jagatha B, Mythri RB, Vali S, et al. Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: therapeutic implications for Parkinson’s disease explained via in silico studies. Free Radic Biol Med 2008;44:907-17.

192. Duvoix A, Blaisis R, Delhalle S, et al. Chemopreventive and therapeutic effects of curcumin. Cancer Lett 2005;223:181-90.

193. Liu L, Zhang W, Wang L, et al. Curcumin prevents cerebral ischemia reperfusion injury via increase of mitochondrial biogenesis. Neurochem Res 2014;39:1322-31.

194. Wu J, Li Q, Wang X, et al. Neuroprotection by curcumin in ischemic brain injury involves the Akt/Nrf2 pathway. PLoS One 2013;8:e59843.

195. Lee YJ, Kim NY, Suh YA, et al. Involvement of ROS in Curcumin-induced Autophagic Cell Death. Korean J Physiol Pharmacol 2011;15:1-7.

196. Thiyagarajan M, Sharma SS. Neuroprotective effect of curcumin in middle cerebral artery occlusion induced focal cerebral ischemia in rats. Life Sci 2004;74:969-85.

197. Kumar R, Saraswat K, Rizvi SI. Potential Therapeutic Impacts of Curcumin Against Age-Related Impaired Cognition and Memory. Curcumin for Neurological and Psychiatric Disorders: Elsevier; 2019. p. 247-55.

198. Kesht WA, Elseady WS, Sarhan NI, et al. Curcumin attenuates cytoplasmic/endoplasmic reticulum stress, apoptosis and cholinergic dysfunction in diabetic rat hippocampus. Metab Brain Dis 2020;35:637-47.

199. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998;281:1309-12.

200. Scheffler IE. Mitochondria: John Wiley & Sons; 2011.

201. Jana NR, Dikshit P, Goswami A, et al. Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. J Biol Chem 2004;279:11680-5.

202. Karmakar S, Banik NL, Patel SJ, et al. Curcumin activated both receptor-mediated and mitochondria-mediated proteolytic pathways for apoptosis in human glioblastoma T98G cells. Neurosci Lett 2006;407:53.

203. Garrido C, Galluzzi L, Brunet M, et al. Mechanisms of cytochrome c release from mitochondria. Cell Death Differ 2006;13:1423-33.

204. Zhou H, Baevers CS, Huang S. The targets of curcumin. Curr Drug Targets 2011;12:320-47.

205. Jayaraj RL, Tamilselvam K, Manivasagam T, et al. Neuroprotective effect of CNB-001, a novel pyrazole derivative of curcumin on biochemical and apoptotic markers against rotenone-induced SK-N-SH cellular model of Parkinson’s...
Curcumin and neuroprotection

disease. J Mol Neurosci 2013;51:863-70.

206. Chhunchha B, Fatma N, Kubo E, et al. Curcumin abates hypoxia-induced oxidative stress based-ER stress-mediated cell death in mouse hippocampal cells (HT22) by controlling Prdx6 and NF-kappaB regulation. Am J Physiol Cell Physiol 2013;304:C636-55.

207. Beckervordersandforth R, Ebert B, Schaffner I, et al. Role of Mitochondrial Metabolism in the Control of Early Lineage Progression and Aging Phenotypes in Adult Hippocampal Neurogenesis. Neuron 2017;93:560-73 e6.

208. Marathe SA, Dasgupta I, Gnanadhas DP, et al. Multifaceted roles of curcumin: two sides of a coin! Expert Opin Biol Ther 2011;11:1485-99.

209. Huang HC, Xue X, Jiang ZF. Curcumin-mediated neuroprotection against amyloid-beta-induced mitochondrial dysfunction involves the inhibition of GSK-3beta. J Alzheimers Dis 2012;32:981-96.

210. Kaytor MD, Orr HT. The GSK3 beta signaling cascade and neurodegenerative disease. Curr Opin Neurobiol 2002;12:275-8.

211. Gonzalez-Salazar A, Molina-Jijon E, Correa F, et al. Curcumin protects from cardiac reperfusion damage by attenuation of oxidant stress and mitochondrial dysfunction. Cardiovasc Toxicol 2011;11:357-64.

212. Mythri RB, Jagatha B, Pradhan N, et al. Mitochondrial complex I inhibition in Parkinson's disease: how can curcumin protect mitochondria? Antioxid Redox Signal 2007;9:399-408.

213. Yoshimura T, Aminura N, Kawano Y, et al. Ras regulates neuronal polarity via the PI3-kinase/Akt/GSK-3beta/CRMP-2 pathway. Biochem Biophys Res Commun 2006;340:62-8.

214. Beaulieu JM, Gainetdinov RR, Caron MG. The Akt
neuroinflammation in Alzheimer's disease. Neural Regen Res 2011;10:1181-9.

215. Giese KP. GSK
signaling cascade in the actions of dopamine. Trends Pharmacol Sci 2007;28:166-72.

216. Freyberg Z, Ferrando SJ, Javitch JA. Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am J Psychiatry 2010;167:388-96.

217. Beaulieu JM, Sotnikova TD, Yao WD, et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A 2004;101:5099-104.

218. Zhu J, Rebecchi MJ, Tan M, et al. Age-associated differences in activation of Akt/GSK-3beta signaling pathways and inhibition of mitochondrial permeability transition pore opening in the rat heart. J Gerontol A Biol Sci Med Sci 2010;65:611-9.

219. Pap M, Cooper GM. Role of translation initiation factor 2B in control of cell survival by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta signaling pathway. Mol Cell Biol 2002;22:578-86.

220. Gartner A, Huang X, Hall A. Neuronal polarity is regulated by glycogen synthase kinase-3 (GSK-3beta) independently of Akt/PKB serine phosphorylation. J Cell Sci 2006;119:3927-34.

221. Endo H, Nito C, Kamada H, et al. Activation of the Akt/GSKbeta signaling pathway mediates survival of vulnerable hippocampal neurons after transient global cerebral ischemia in rats. J Cereb Blood Flow Metab 2006;26:1479-89.

222. Zhang X, Yin WK, Shi XD, et al. Curcumin activates Wnt/beta-catenin signaling pathway through inhibiting the activity of GSK-3beta in APPsw6 transfected SY5Y cells. Eur J Pharm Sci 2011;42:540-6.

223. Kirov SM, Pirogov NI. Clinical Pathophysiology. Medical Principles and Practice 2018;24.

224. Hoppe JB, Coradini K, Frozza RL, et al. Free and nanoencapsulated curcumin suppress beta-amyloid-induced cognitive impairments in rats: involvement of BDNF and Akt/GSK-3beta signaling pathway. Neurobiol Learn Mem 2013;106:134-44.

225. Huang HC, Tang D, Xu K, et al. Curcumin attenuates amyloid-beta-induced tau hyperphosphorylation in human neuroblastoma SH-SY5Y cells involving PTEN/Akt/GSK-3beta signaling pathway. J Recept Signal Transduct Res 2014;34:26-37.

226. Venigalla M, Gyuenges E, Munch G. Curcumin and Apigenin - novel and promising therapeutics against chronic neuroinflammation in Alzheimer's disease. Neural Regen Res 2015;10:1181-5.

227. Feng HL, Dang HZ, Fan H, et al. Curcumin ameliorates insulin signalling pathway in brain of Alzheimer's disease transgenic mice. Int J Immunopathol Pharmacol 2016;29:734-41.

228. Xiao Y, Zhao S, Gao Y, et al. Curcumin pretreatment attenuates inflammation and mitochondrial dysfunction in...
experimental stroke: The possible role of Sirt1 signaling. Brain Res Bull 2016;121:9-15.

229. Seo JH, Rah JC, Choi SH, et al. Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. FASEB J 2002;16:1826-8.

230. Grimes CA, Jope RS. CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. J Neurochem 2001;78:1219-32.

231. Meffre D, Massaad C, Grenier J. Lithium chloride stimulates PLP and MBP expression in oligodendrocytes via Wnt/beta-catenin and Akt/CREB pathways. Neuroscience 2015;284:962-71.

232. Alda M, Shao L, Wang JF, et al. Alterations in phosphorylated cAMP response element-binding protein (pCREB) signaling: an endophenotype of lithium-responsive bipolar disorder? Bipolar Disord 2013;15:824-31.

233. Quiroz JA, Gould TD, Manji HK. Molecular effects of lithium. Mol Interv 2004;4:259-72.

234. Ashrafizadeh M, Rafiei H, Mohammadnejad R, et al. Potential therapeutic effects of curcumin mediated by JAK/STAT signaling pathway: A review. Phytother Res 2020.

235. Dai W, Wang H, Fang J, et al. Curcumin provides neuroprotection in model of traumatic brain injury via the Nrf2-ARE signaling pathway. Brain Res Bull 2018;140:65-71.

236. Jia L, Pina-Crespo J, Li Y. Restoring Wnt/beta-catenin signaling is a promising therapeutic strategy for Alzheimer's disease. Mol Brain 2019;12:104.